Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 28th, 2026

LECO_Weekly-Healthcare-News_9-28-2026Download

Healthcare Weekly News and Deals – Sept 28th, 2026

  1. Webster Equity Partners to acquire Lifecore Biomedical (NASD: LFCR) for $6.28 per share in cash plus CVRs, valuing the sterile-injectable CDMO at up to $663.7 million. Lifecore is a Chaska, Minnesota contract manufacturer for sterile injectables — syringes, vials and cartridges, including complex formulations — and a large producer of injectable-grade hyaluronic acid. Common holders get $6.28 a share in cash, a 49.5 percent premium to the September 25 close. Contingent value rights tied to 2028 and 2029 revenue and 2030 EBITDA can add $160 million in the aggregate, or $9.67 a share if every milestone hits. MidCap Financial, MSD Partners and Alcon committed the debt; Webster committed the equity. The merger agreement includes a 30-day go-shop. The company stays in Chaska under the Lifecore name, with a close aimed at year-end. (Link)
  2. Ardan Equity is investing in clinical trial technology company Clinical ink alongside existing backer GI Partners at a total enterprise value of more than $500 million. Healthcare software specialist Ardan Equity is investing in Clinical ink, the clinical trial technology company, alongside existing backer GI Partners. GI Partners acquired a majority interest in Clinical ink in August 2020, when prior investor NovaQuest stayed on as a minority holder and management invested significantly. The new round adds a sponsor that invests exclusively in healthcare software, while GI Partners keeps its exposure as Clinical ink builds on a platform that brings data, technology and patient science together for trial sponsors. (Link)
  3. Clearlake Capital Group and Charlesbank Capital Partners have agreed to inject approximately $175 million of preferred equity into distressed healthcare software provider Symplr, as part of a creditor-backed recapitalization designed to shore up its finances and extend its debt maturities. Clearlake Capital Group and Charlesbank Capital Partners will provide around $175 million of preferred equity to Symplr under a restructuring agreed with several creditor groups, with the sponsors deferring interest on newly issued junior debt to preserve cash. Second-lien lenders are expected to add $103.5 million through a first-out second-lien loan, while first-lien holders would receive a 100-basis-point coupon increase for extending the 2027 maturity by three years. Symplr’s roughly $1.2 billion first-lien term loan was recently quoted near 71.4 cents on the dollar amid concerns over AI’s impact on software. Company is held in a single-asset continuation vehicle. (Link)
  4. Existing shareholders Star One Global Capital Limited and Eliyahou Harari have fully funded an $18 million registered direct offering in Nasdaq-listed capsule endoscopy developer CapsoVision (CV), buying 3,163,444 shares at $5.69 each. CapsoVision (CV) has raised about $18 million through a registered direct offering funded entirely by existing shareholders Star One Global Capital Limited and Eliyahou Harari. Under a September 17 securities purchase agreement, the investors agreed to buy 3,163,444 shares at $5.69, a roughly 5% discount to the prior Nasdaq close, with no underwriter involved. The insider-backed raise, approved by the board and reviewed by the audit committee, strengthens the balance sheet of the Saratoga, California-based capsule endoscopy developer, which has a market value of about $299.8 million. Proceeds will fund sales and marketing, R&D and working capital as it advances AI-assisted CapsoCam Plus and a second-generation colon capsule. (Link)
  5. Lexeo Therapeutics (NASD: LXEO) has agreed to acquire Mantle Therapeutics for $8.3 million in cash and equity plus up to $13 million in milestones, adding Friedreich ataxia programs. Mantle is a private clinical-stage company with four Friedreich ataxia candidates designed to raise or replace frataxin in the brain. One is an oral combination already in patients; another is an RNA construct linked to an anti-TfR1 antibody fragment. On the same day Lexeo signed a sponsored-research agreement with Weill Cornell on intra-cisternal dosing of LX2006 and took options from Vivet Therapeutics and Apertura Gene Therapy. Management says the cash on hand still lasts into 2028. The acquisition is expected to close this quarter. (Link)
  6. Avesi Partners has made an investment in St. Louis-based New Age Medical, a spinal MedTech hub connecting manufacturers, sales reps, hospitals and surgeons. Avesi invests in lower-middle-market healthcare services and technology and now has more than $2.2 billion under management. New Age sits between implant makers and the operating room: more than 85 OEMs, 100-plus independent reps, 200-plus hospitals and surgery centers, and 350-plus spine surgeons. Founder and chief executive Kevin Bly remains in place with the current management team. The check is meant to move product from the plant to the table faster, not to recapitalize a clinic chain. (Link)
  7. GoodVets has acquired WellHaven Pet Health, adding more than 40 veterinary hospitals and taking the combined network from 75 to 116 locations. GoodVets, based in Chicago, has mostly opened hospitals from scratch with local veterinarians. WellHaven already runs more than 40 clinics across seven states, with clusters in the Pacific Northwest and the Midwest. Those sites will move onto GoodVets’ central operating model and, over time, onto the GoodVets name. Existing clinic teams and patient panels stay in place. Terms were not published. (Link)
  8. Prisma Health has agreed to acquire 36 South Carolina urgent care centers, formerly Doctor’s Care, from Novant Health. Novant had been running the former Doctor’s Care sites. Closing is set for November 1, when the clinics convert to the Prisma Health Urgent Care name and about 500 employees come across. Patients keep walk-in, booked and virtual visits — including respiratory tests, X-ray and labs — and gain a referral path into Prisma’s hospitals and specialists. Most locations stay put; a few may fold into a neighboring center, with affected staff offered jobs nearby. Purchase price was not disclosed. (Link)
  9. Forge, the B2B events and media company backed by Apollo Funds (APO), has agreed to acquire Becker’s Healthcare from Pamlico Capital, combining it with Fierce Healthcare and Life Sciences to create a scaled healthcare and life sciences media and events platform. Forge, formed by combining Emerald and Questex after their acquisition by Apollo Funds (APO) in July 2026, has signed a definitive agreement to acquire Chicago-based Becker’s Healthcare from Pamlico Capital. The deal includes Becker’s 16 annual conferences, more than a dozen digital publications and its newsletters, podcasts and executive communities, which reach over 1.5 million healthcare leaders. Combined with Forge’s Fierce Healthcare and Life Sciences, the platform will run more than 35 live events. (Link)
  10. May River Capital has sold Addison, Illinois-based environmental monitoring platform Dickson to Copeland, a portfolio company of Blackstone (BX), expanding Copeland’s cold chain monitoring capabilities for healthcare and life sciences customers. May River Capital has sold Dickson to Copeland, a Blackstone (BX) portfolio company with approximately 18,000 employees across more than 40 countries. May River acquired Dickson in April 2018 and turned the family-owned, single-site business into a global environmental monitoring platform serving customers in more than 50 countries from Illinois, France and Malaysia. During its ownership, May River invested in next-generation sensing and cloud-based monitoring and took private Oceasoft, a publicly traded French monitoring company. Dickson serves regulated life sciences, pharmaceutical, healthcare and medical device customers, advancing Copeland’s cold chain intelligence offering (Link)
  11. Arcventis Health Partners has made a majority growth investment in Chicago-based functional medicine and hormone health provider Aligned Modern Health, with existing investor Harbour Point Capital remaining a meaningful shareholder, to fund national telehealth expansion and the launch of peptide therapy. Arcventis Health Partners, a US healthcare investor with growth equity and growth buyout strategies, has taken a majority stake in Aligned Modern Health, while Harbour Point Capital stays on as a meaningful investor. AMH operates 15 clinics across Chicago, a telehealth practice serving patients in more than 20 states and a team of 100-plus clinicians spanning functional medicine, hormone replacement therapy, chiropractic care and acupuncture. The capital will fund national expansion, broader clinical offerings including newly launched peptide therapy, the digital patient experience and provider hiring. AMH accepts most major insurance, which sets it apart from self-pay and concierge models. No valuation was disclosed. (Link)
  12. 1315 Capital has led a growth capital investment in Richmond, Texas-based medical device developer and manufacturer Velentium Medical, joining existing investor Great Point Partners as a significant shareholder to scale commercial manufacturing of wearable and implantable devices. Philadelphia-based 1315 Capital, which manages over $1 billion, led a growth capital investment in Velentium Medical, a developer and manufacturer of active Class II wearable and Class III implantable medical devices. Great Point Partners, which manages about $1.7 billion, remains a significant shareholder. Velentium operates from a 50,000-square-foot manufacturing facility after expanding from an engineering shop into commercial production. Proceeds go to manufacturing capacity, product development and regulatory infrastructure. 1315 takes minority and majority stakes in commercial-stage healthcare and outsourced medtech companies. (Link)
  13. Newly launched Boston private equity firm Haelan Capital Partners has made its first investment in Boca Raton, Florida-based virtual acute care provider NuView Health, pairing its capital with an in-house team of experienced healthcare operators. Boston-based Haelan Capital Partners launched with an investment in NuView Health, a hybrid onsite and virtual care partner to hospitals and provider groups across ICU, neurology, stroke and infectious disease. Founded by Gregg Osenkowski and Scott Castle, Haelan pursues control buyouts of founder-owned, lower middle market tech-enabled healthcare services businesses. Its Growth Enablement Model places an in-house C-suite of healthcare operators alongside the investment team to build portfolio infrastructure. NuView has about 150 active providers across more than 60 facilities and a 15-year clinical track record, and its doctors have treated over one million US patients. No deal value was announced. (Link) (Link)
  14. 5th Century Partners has completed a strategic investment in ION PT Network, a founder-led physical therapy management company serving the workers’ compensation market, to refine its commercial strategy while preserving its clinician-led model. Chicago-based 5th Century Partners, which invests in lower middle-market healthcare and business services companies, has made a strategic investment in ION PT Network. Founded in 2017 by physical therapist Joseph Noel, ION manages workers’ compensation physical therapy for payers, employers and third-party administrators through independent providers, assigning each referral to a licensed clinical case owner; more than half its staff are licensed therapists. 5CP plans to refine ION’s business and commercial strategy while preserving its clinical model. Noel remains CEO, supported by newly added chief revenue officer Sara Mulick and chief financial officer Alina Schreiber. Terms were not disclosed. (Link)
  15. Ascend Learning has acquired AI-powered healthcare workforce scheduling platform M7 Health, combining it with its StaffGarden and Laudio brands to support clinicians from schooling through day-to-day staffing. Boston-based Ascend Learning, a healthcare and learning technology company, has acquired M7 Health, whose AI platform forecasts staffing demand, balances schedules and recruits to fill gaps for health systems ranging from academic medical centers to rural hospitals. M7 customers have cut administrative burden by more than 60%, premium labor spend by 35% and nurse turnover by 30%. The deal pairs M7 with Ascend’s StaffGarden and Laudio brands, extending a platform that supports more than 60% of nursing schools and 245,000 allied health professionals a year. It follows Ascend’s August acquisition of TAMS, continuing its expansion in healthcare workforce technology. Terms were not disclosed. (Link)
  16. Carisk Partners has acquired onsite occupational healthcare provider FirstCare Onsite to connect injured workers with care from the point of injury through complex recovery in the workers’ compensation market. Tampa-based Carisk Partners, a specialty risk transfer, care coordination and clinical services company in workers’ compensation, has acquired FirstCare Onsite. FirstCare places clinicians at employer worksites and has historically resolved roughly 30% of workplace injuries before they became claims. Carisk will keep FirstCare’s onsite model while routing complex cases into its specialty care, complex care management and behavioral health services. Carisk plans to invest in expanding FirstCare’s onsite programs, particularly among large employers with concentrated workforces. (Link)
  17. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, entering Arkansas as its seventh state and expanding in-home care for medically complex pediatric and adult patients. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, which has served medically complex Arkansas patients for more than three decades, including children and adults who depend on ventilators or tracheostomies. The carve-out let’s Care IV focus exclusively on its Medicare intermittent skilled home health business. MGA is keeping the division’s leadership, headed by Joseph Kennon, and its nursing workforce, and plans to use the unit to reach rural and underserved patients and pursue value-based partnerships with health plans. MGA now has more than 5,500 team members serving over 6,000 patients daily across seven states. Terms were not disclosed. (Link)
  18. Nashville-based Chord Specialty Dental Partners has entered Ohio by partnering with Ohio-based pediatric practices Prairie Kids Dental of West Jefferson and Clover Kids Dental of Columbus, extending its network to eight states. Chord Specialty Dental Partners, a Nashville-based dental support organization, has partnered with two Ohio pediatric practices: Prairie Kids Dental in West Jefferson and Clover Kids Dental in Columbus. Both practices are led by founder Kimberly Gill, DDS. The deal marks Chord’s entry into Ohio and brings its footprint to eight states. Chord supports more than 60 partner practices across pediatric dentistry, orthodontics, oral surgery and ambulatory surgery centers. The deal adds to an active consolidation market: professional services, the segment Healthcare DealHub files it under, leads that site’s 2026 year-to-date healthcare deal count with 386 transactions. Terms were not disclosed. (Link)
  19. Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person West Michigan autism services provider, nearly doubling the footprint of its Center for Autism. Michigan’s Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person provider of Applied Behavior Analysis, psychological assessment and counseling with locations in Grand Rapids, Holland and Georgetown Township. The deal nearly doubles the footprint of Hope Network’s Center for Autism, which operates in Kentwood, Holland Township, Livonia and Okemos. Financial terms were not released. Integration is planned in phases through about spring 2027. DE locations, clinicians and care models stay in place, with no immediate rebranding. (Link)
  20. Penn Medicine, Independence Blue Cross (IBX) and Regent Surgical have formed a new joint company to develop at least 18 ambulatory surgery centers across Greater Philadelphia, combining health-system, payer and ASC operator capabilities to shift procedures into lower-cost outpatient settings. Penn Medicine, Independence Blue Cross and Regent Surgical are launching a new company to develop at least 18 ambulatory surgery centers across Pennsylvania, New Jersey and Delaware. Penn brings the clinical network, IBX the payer, and Regent the ASC development and operating platform. Hospital facility fees can run close to twice ASC fees; Vizient has projected outpatient surgical volumes up 20 percent through 2035. No financial terms were disclosed. (Link)
  21. OceanSound Partners-backed PAR Excellence Systems, based in Cincinnati, Ohio, has acquired Madison, Wisconsin-based healthcare RFID inventory tracking company Terso Solutions from Promega Corporation to build a unified hospital inventory management platform. PAR Excellence Systems, an OceanSound Partners portfolio company, has acquired Terso Solutions from its parent, Promega Corporation. Terso makes ultra-high-frequency RFID enclosures, open-air readers and cloud software that let hospitals track high-value inventory in real time, with thousands of enclosures installed across hundreds of hospitals and health systems, including the US Department of Veterans Affairs. The companies have worked together for years, and hundreds of PAR clients already connect Terso enclosures to PAR’s TrackCore tissue and implant tracking software. The combined business serves about 1,700 hospitals, nearly 30% of the roughly 6,000 in the US, and aims to replace fragmented point solutions. Financial terms were not disclosed. (Link)
  22. RS2 Healthcare Partners has completed its first new platform investment since refocusing exclusively on healthcare, backing Hatboro, Pennsylvania-based medical device contract manufacturer KMM Group and appointing J. Mark King as CEO. Boston-based RS2 Healthcare Partners, formerly Riverside Partners, has invested in KMM Group, a vertically integrated precision contract manufacturer of complex, tight-tolerance components for the medical device industry. The deal is RS2’s first new platform since the firm rebranded earlier this year to focus exclusively on lower middle-market healthcare; RS2 has raised $1.6 billion in total commitments since its 1989 founding. RS2 appointed J. Mark King, previously CEO of former RS2 portfolio company Tegra Medical, as KMM’s president and CEO. Founders John Shegda and Eric Wilhelm stay on as chief technology officer and executive vice president of business transformation, respectively. No terms were announced. (Link)
  23. Arlington Capital Partners portfolio company AVS Bio has acquired Cambridge, UK-based bio-reagent supplier Biorbyt Ltd. to expand its biomaterials catalog and ecommerce capabilities. AVS Bio, a Norwich, Connecticut provider of bioprocessing inputs and services backed by Arlington Capital Partners, has acquired Biorbyt Ltd., a Cambridge, UK supplier with more than 1 million SKUs of antibodies, proteins, ELISA kits and molecular biology reagents. The add-on expands AVS Bio’s research catalog and adds Biorbyt’s ecommerce channel. Arlington is investing from its $6 billion Fund VII. Biorbyt’s leadership team stays in place. (Link)
  24. Audax Private Equity-backed Elevate ENT Partners has acquired West Texas Ear, Nose & Throat, expanding its otolaryngology physician practice management platform across Texas. Elevate ENT Partners, backed by Audax Private Equity, has acquired West Texas Ear, Nose & Throat, which operates locations in Abilene and Brownwood. The practice is led by its sole physician, Dr. Jason Acevedo, with 11 healthcare and administrative staff, and provides otolaryngology, head and neck surgery and allergy treatment. The deal is Elevate’s first practice acquisition of 2026 and extends its reach across Texas. Elevate supports a national network of more than 80 otolaryngology centers and over 130 affiliated physicians. It gives physician-led ENT and allergy practices management infrastructure, revenue cycle management, payer contracting, human resources and operational scale. Financial terms were not disclosed. (Link)
  25. Rays of Belief Limited (MOMSBELIEF), operating as Mom’s Belief, has acquired 100% of New York-based pediatric Early Intervention provider City Pro Group through its subsidiary Mom’s Belief US Inc. to build a US developmental care platform. India-based Rays of Belief (MOMSBELIEF), which runs 136 developmental care centres under the Mom’s Belief brand, has acquired all of City Pro Group through wholly owned subsidiary Mom’s Belief US Inc., effective September 18, 2026. Founded in 1995, CPG provides pediatric Early Intervention and special education services across the Bronx, Brooklyn, Manhattan and Long Island. CPG generated US$11.43 million (about ₹97.27 crore) of FY25 revenue, more than the acquirer’s FY26 consolidated revenue of ₹81.66 crore, so the deal could roughly double the group’s scale. The acquisition gives the company a US operating platform and a two-way exchange of clinical know-how between India and the US. Consideration was not disclosed. (Link)

Venture Deals and Other

  1. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences investment fund have co-led Precision Neuroscience’s oversubscribed $250 million Series D, joined by Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent Korea Investment Holdings, KRX: 071050), Hitachi Ventures (parent Hitachi, TYO: 6501) and JSL Health Capital, to advance its brain-computer interface toward commercialization. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences fund co-led Precision Neuroscience’s oversubscribed $250 million Series D, lifting total capital raised to $430 million since the brain-computer interface developer was founded in 2021. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent KRX: 071050), Hitachi Ventures (parent TYO: 6501) and JSL Health Capital also joined, spanning sovereign wealth, venture, public-market and family-office capital. Precision holds FDA clearance for its Layer 7 cortical interface, has completed more than 100 procedures across 18 institutions and partners with Medtronic (MDT). Proceeds will fund clinical expansion, further FDA review and commercialization. (Link)
  2. Francisco Partners has led a $155 million Series E in pharmacy benefit management and care navigation company Rightway, with participation from existing investors Thrive Capital and Khosla Ventures, to expand its AI and technology capabilities. Francisco Partners led a $155 million Series E in New York-based Rightway, with existing investors Thrive Capital and Khosla Ventures participating. Rightway provides pharmacy benefit management and care navigation for employers. Its financial model removes any incentive to profit from higher drug spend, and pharmacists guide members to the most appropriate medications at the lowest cost. It now counts 45 Fortune 500 companies as clients, nearly 10% of the index. Its SureSpend model caps total pharmacy spend and covers GLP-1s and rare high-cost drugs at net cost with 100% rebate pass-through. Proceeds will expand Rightway’s AI and technology. Francisco Partners, with over $75 billion raised, brings healthcare technology expertise. (Link)
  3. .406 Ventures has led a $22 million Series A in at-home cervical cancer screening company Teal Health, with continued backing from Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures and new participation from Japan-based MPower Partners, ahead of broad insurance coverage in 2027. .406 Ventures led a $22 million Series A in Teal Health, maker of the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures returned, and Japan-based MPower Partners joined, lifting total funding to $45 million. Federal guidelines due in January 2027 require most health plans to cover self-collection screening. Proceeds go to payor, health system, employer and provider contracts, direct-purchase channels and hiring. Teal reports that 59 percent of women who use the wand had been underscreened. (Link)
  4. NEA has led a $20 million Series A in Nashville-based AI post-acute admissions platform Basalt Health, with participation from existing investors Frist Cressey Ventures and 25m Health, to scale across Lifepoint Health and ScionHealth hospitals. Return investor NEA led a $20 million Series A in Nashville-based Basalt Health, with existing backers Frist Cressey Ventures and 25m Health, 25madison’s healthtech venture studio, participating; total funding now stands at about $24.5 million. Basalt’s AI reads post-acute referrals and checks them against clinical and payer rules, cutting median processing time by 86% at Lifepoint Health. The capital will support scaling across 111 markets by the end of 2026, including 62 ScionHealth hospitals and 49 Lifepoint markets, plus expansion into discharge and payer workflows. NEA, with more than $38 billion in assets under management, and Frist Cressey, with $846 million, bring deep healthcare networks. (Link)
  5. Accel has led a $10 million seed round in New York-based healthcare conversational AI company Clarion Health, with participation from Y Combinator, to automate scheduling, referrals, prescription refills and patient communications for providers. Accel led a $10 million seed round in New York-based Clarion Health, with participation from Y Combinator. Clarion’s conversational AI platform automates scheduling, referrals, prescription refills and patient communications for healthcare providers. Founded in 2024 by Ryan Gallagher and Jeffrey Lamothe, the company is building what Y Combinator calls an AI communication layer for healthcare, with agents that handle the overwhelming volume of calls and messages providers receive. The Accel-led round gives the two-year-old startup capital to scale its AI communication infrastructure for healthcare providers, and the company is actively hiring following the raise. (Link)
  6. Surgeon investors have backed Redefine Surgery’s oversubscribed pre-seed round, bringing total capital raised to $10 million, as Catalyst OrthoScience joins as Founding Partner to co-develop surgical intelligence for shoulder replacement. Redefine Surgery has closed an oversubscribed pre-seed round backed mostly by surgeon investors, bringing total capital raised to $10 million. The company is combining computer vision, software and robotics in a portable platform for the operating room, starting in orthopedics. Naples, Florida-based Catalyst OrthoScience joined as founding partner on surgical intelligence for shoulder replacement. More than 25 surgeons advise the company. Commercial use still requires regulatory clearance. (Link)
  7. Ground State Ventures has led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors, to build physics-based AI models for drug and materials simulation. Ground State Ventures led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors. Azulene builds physics-based models trained on quantum-mechanical data for drug and materials simulation. Co-founder Nicolas Sawaya previously led quantum chemistry algorithm work at Intel Labs. Proceeds go to hiring and to work with biotech and industrial chemistry customers. (Link)
  8. Elmstead Partners, Chisos Capital, the Chemical Angel Network and individual angel investors have backed Axio BioPharma’s $2.4 million pre-seed round to connect biomanufacturing data between pharma companies and their manufacturing partners. Elmstead Partners, Chisos Capital, the Chemical Angel Network and a group of individual angels invested in Axio BioPharma’s $2.4 million pre-seed round. The Madison, Wisconsin company connects manufacturing data between drug sponsors and their manufacturing partners through a product called Lattice, with each side keeping its own systems. Proceeds fund first deployments with design partners and further work on Rosetta, an ontology layer that maps those systems to each other. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 21st, 2026

LECO_Weekly-Healthcare-News_9-21-2026Download

Healthcare Weekly News and Deals –Sept 21st, 2026

  1. CareTrust REIT (NYSE: CTRE) Acquires Southwest Skilled-Nursing Portfolio for $400 Million First public print of a transaction effective September 1. The book is 2,622 licensed SNF beds, triple-net to the incumbent operator with inflation escalators and renewal options. Structured as a joint venture; CareTrust put in about $380 million from cash and settled equity forwards and models an 8.6% stabilized yield. Sourced off-market in markets where both landlord and operator already have scale. Year-to-date deployment is now about $1.9 billion and Q3-to-date about $710 million. Management reloaded the near-term pipeline at about $600 million. (Link)
  2. Lisata Therapeutics (NASD: LSTA) Acquires Marea Therapeutics; $225 Million PIPE Concurrent Stock-for-stock reverse merger plus PIPE. RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive, Sofinnova, Omega, Surveyor/Citadel, Columbia Threadneedle, Nantahala, Affinity, venBio and Rock Springs filled the round. Combined cap table: legacy Lisata about 2.4%, Marea holders about 59.5%, PIPE about 38.1%. Assets are MAR001/005, an ANGPTL4 monoclonal in Phase 2b for severe hypertriglyceridemia, and MAR002, a growth-hormone-receptor antagonist headed to Phase 2 in acromegaly. Runway into 2028; key reads targeted for the fourth quarter of 2027. (Link)
  3. Veracyte (NASD: VCYT) acquires Convergent Genomics for $150 million in cash plus up to $30 million in milestone payments, adding urine-based bladder cancer testing. Veracyte closed its purchase of Convergent Genomics on September 14. It paid $150 million in cash at closing, subject to customary adjustments, with up to $30 million more tied to UroAmp publication and reimbursement milestones. Convergent was founded in 2015 in partnership with Oregon Health & Science University and runs a CLIA-certified lab in South San Francisco. Its UroAmp urinary tumor DNA assay is validated for monitoring therapy response and post-treatment surveillance in non-muscle-invasive bladder cancer. The asset sits alongside Decipher Bladder and TrueMRD, so Veracyte now covers urine, tissue and blood across the bladder cancer pathway. Management expects no material impact on 2026 EBITDA guidance. (Link)
  4. Oaktree commits up to $115 million in milestone-based capital to Saol Therapeutics ahead of the FDA decision date for SL1009. Funds managed by Oaktree will provide up to $115 million to Saol Therapeutics, a private clinical-stage drug company in Roswell, Georgia. An initial tranche funds launch preparation, and the rest is released as regulatory, clinical and commercial milestones are met. The lead drug, SL1009 (sodium dichloroacetate), treats pyruvate dehydrogenase complex deficiency, a rare mitochondrial disease with no approved therapy. The FDA rejected an earlier application in 2025. Saol resubmitted, and the FDA’s decision date is December 30, 2026. Later tranches would fund SL1009 in congenital lactic acidosis and expand SL1002 into more pain indications and spasticity. (Link)
  5. Agora makes a $47 million first investment in Vheda Health, a Columbia, Maryland outcomes and analytics platform for health plans. Agora is a San Francisco private equity firm focused on healthcare technology, founded by Neil Vangala. It has invested $47 million in Vheda Health. This is Agora’s first deal and the first institutional capital in Vheda’s 13-year history. The previously bootstrapped company runs chronic-condition and maternity programs for high-risk Medicaid, Medicare and Special Needs Plan members. It cites more than $975 million in savings for health plan partners and an average 3:1 return on investment. Co-founder and CEO Shameet Luhar stays. The money funds expansion beyond 18 states, new analytics products and targeted acquisitions. (Link)
  6. Ambu (Nasdaq Copenhagen: AMBU B) acquires U.S.-based TIMS Medical (Foresight Imaging) for $45 million upfront plus up to $20 million in milestones to advance its EndoIntelligence platform. Ambu, the Danish single-use endoscopy leader, has bought Foresight Imaging, LLC, which trades as TIMS Medical. It is paying $45 million upfront and up to $20 million in milestones, for total consideration of as much as $65 million. Founded in 2004, TIMS builds hardware and software that record procedure imaging and integrate it into hospital EMR and imaging systems. Its flagship TIMS MVP is widely used in ENT procedures, including FEES exams. The business has about 55 employees, roughly $15 million in annual revenue and around 7,000 installations across U.S. hospitals. Ambu expects the deal to accelerate revenue growth and kept its FY2025/26 outlook unchanged. (Link)
  7. WJRJJ Ventures, owned by Copart (NASD: CPRT) founder Willis Johnson, completes a $40 million private placement in HealthStream (NASD: HSTM). WJRJJ Ventures bought 1.5 million HealthStream shares at $29.50 each. That comprised 1,355,932 new shares for about $40 million and 144,068 existing shares bought from CEO Robert Frist Jr. for about $4.25 million. Frist remains the largest shareholder, with about 16.4%. Johnson, a Nashville-area entrepreneur, was also the first investor in Empath Nursing, founded in 2025. HealthStream sells workforce technology to hospitals and will use the money for product investment and possible acquisitions. (Link)
  8. Arsenal Capital Partners–backed Endpoint Clinical acquires Boston-based Bluefin, a clinical supply forecasting and planning technology provider. Endpoint Clinical, the randomization and trial supply management vendor Arsenal acquired in 2024, has bought Bluefin, a Boston cloud platform for planning clinical supply demand and distribution. The add-on moves Endpoint upstream from RTSM execution into forecasting. Supply plans will link to live enrollment and inventory data, so sponsors can anticipate shifts rather than react to them. Bluefin will keep operating independently and will still connect to competitors’ RTSM systems. Endpoint will add implementation, quality, project management and customer support. Bluefin CEO Andy Maltun stays. (Link)
  9. Seven Hills Capital–backed Spa Medicca of Canton, Ohio acquires Dr. Nicholas E. Sherock LLC & Associates, an Ohio women’s health practice in Massillon and Orrville. Spa Medicca has acquired Dr. Sherock & Associates, a two-location women’s health group in Massillon and Orrville. Dr. Nicholas Sherock leads a five-person clinical team offering gynecologic care, hormone replacement therapy, minimally invasive surgery and aesthetic services. Those services map onto Spa Medicca’s focus on medical aesthetics, hormone optimization and women’s health. The deal adds density in northeast Ohio after earlier work such as Amy Brenner, MD & Associates in Cincinnati. Patients keep existing providers and locations. (Link)
  10. Gauge Capital–backed Reliable Medical acquires Freedom in Mobility and Action Seating & Mobility, expanding CRT coverage across Alabama, Tennessee, Oklahoma, Arkansas and Colorado. Reliable Medical is a Nashville CRT and home medical equipment provider Gauge recapitalized from Seven Hills in January. Freedom in Mobility adds three sites in north Alabama and Tennessee; president Teresa Glass Owens and COO Forrest Owens join. Action Seating & Mobility adds Tulsa, Oklahoma City, Muskogee, Fayetteville, Sherwood and Denver — manual and power chairs, custom seating, ATP-led fitting and repair. Combined network is more than 50 locations. Two add-ons in one week on the same platform. (Link)
  11. NMS Capital launches Asurgence Medical by recapitalizing ENDOCORP and acquiring Medical Optics from Probo Medical. NMS partnered with management to recapitalize Endoscopy Corporation of America of Southfield, Michigan and at the same time bought Medical Optics of Tamarac, Florida from Probo Medical. ENDOCORP supplies more than 15,000 repair-part SKUs for flexible endoscopes. Medical Optics repairs and resells flexible and rigid scopes across manufacturers. Both keep their names as Asurgence subsidiaries. Former Probo CEO Michael Asmer becomes CEO. Thesis is aging equipment fleets and hospital pressure to avoid OEM overhaul pricing. (Link)
  12. Amulet Capital Partners closes a continuation vehicle to recapitalize US Fertility. New and existing investors participated. US Fertility was formed in 2020 and now supports more than 120 clinic and IVF lab locations and over 200 physicians. It has treated more than 400,000 patients. The deal builds on L Catterton’s 2025 entry as co-lead alongside Amulet and the physician partners. Amulet, a healthcare-only sponsor managing about $3.8 billion, stays involved. The new capital funds geographic expansion and clinical innovation. (Link)
  13. Sheridan Capital Partners acquires a majority stake in PtEverywhere, a Raleigh-based practice management and payments platform for physical therapy clinics. Sheridan completed a majority investment in PtEverywhere. The Raleigh platform brings scheduling, clinical documentation, billing and collections into one workflow for small and mid-sized outpatient physical therapy clinics, including cash-pay and hybrid reimbursement models. CEO Andrew Shofner stays. Sheridan plans organic growth and add-ons that broaden the product into adjacent rehab segments. The deal sits next to Sheridan’s 2025 investment in post-acute billing vendor National Care Systems. (Link)
  14. Martis Capital– and Din Ventures–backed Archway Dental Partners acquires Veale Dental, its first Massachusetts practice. Archway Dental Partners, based in Danbury, Connecticut, acquired Veale Dental, a two-location general practice in South Easton and Dartmouth. This is Archway’s first Massachusetts practice and its third acquisition of 2026, after five deals in 2025. The group began as the four-location Dental Associates of Connecticut and now supports more than 40 practices across Connecticut and New York. Entry into a new state rather than an add-on in an existing market. (Link)
  15. Neuberger and KKR (NYSE: KKR) agree to acquire a significant minority stake in Datavant, which remains controlled by New Mountain Capital. Funds managed by Neuberger Capital Solutions and Neuberger Private Markets, together with KKR’s Strategic Investments Group, agreed to buy a significant minority stake in Datavant. New Mountain Capital, an investor since 2014, keeps control. Datavant’s network spans more than 80,000 providers and 75 of the top 100 health systems, and its data touches about 90% of the U.S. population. Growth capital into a scaled asset rather than an exit, funding further digitization and clinical AI. Closing expected in the fourth quarter of 2026. (Link)
  16. Parthenon Capital–backed MRO acquires Vyne Medical from TJC-owned Vyne, adding clinical data intake and document processing. MRO, a Norristown clinical data management platform, acquired Vyne Medical from Vyne, a TJC portfolio company. Vyne Medical turns paper, fax, voice and image inputs into structured data for more than 800 hospitals. Together the companies serve over 2,500 hospitals and 35,000 clinics. Intake tools feed MRO’s medical-records release and data exchange services. Vyne Dental is not part of the deal and stays with TJC. Clean sponsor-to-sponsor handoff. (Link)
  17. NewSpring-, Kineticos-, HealthQuest- and Great Point–backed Kincell Bio Merges with Cellipont to Form Kincellis Advanced Therapies U.S. cell-therapy CDMO combination. Kincell’s immune-cell shop plus Cellipont’s stem, iPSC, MSC, dendritic, exosome and mRNA work. About 140,000 square feet across Gainesville, Research Triangle Park and The Woodlands; 16 qualified GMP suites; more than 150 GMP batches released; 10 INDs this year; 200-plus staff. Darren Head is CEO. Equity led by NewSpring with Kineticos Life Sciences, HealthQuest Capital and Great Point Partners; debt from J.P. Morgan. (Link)
  18. Arlington-Backed Everest Clinical Research Acquires Firma Clinical’s Data Services Unit Toronto data-first CRO buying Firma DS, a biometrics and clinical-data book that has touched more than 1,000 studies and 60-plus NDAs across oncology, neurology, rare disease, hepatology and nephrology. Adds delivery capacity in the U.S. and Asia-Pacific. Firma DS clients get Everest’s full-service stack — regulatory, operations, safety, medical writing — on one CRO. Arlington Capital has owned Everest since 2020. (Link)
  19. Gauge-Backed Rovia Clinical Research Acquires Pinnacle Research Group and Cullman Clinical Trials in Alabama Site-network add-ons on Gauge’s Rovia platform. Pinnacle is an Anniston-area multi-specialty site founded in 1998, with 500-plus completed trials and Phase I capability. Cullman Clinical Trials is its north-central Alabama partner site. The pair gives Rovia owned density in a state it did not previously control. Gauge has funded the site roll-up since the 2024 platform launch. Separate from Reliable Medical, another Gauge healthcare vehicle. (Link)
  20. HealthEdge- and United Western–Backed Veridian Healthcare Acquires ScarScience from Mitchell-Vance Medical-grade silicone scar sheets and gels into plastic surgery, dermatology and physical-therapy channels. Brand add-on onto a wound-and-scar distribution platform rather than a clinic buy. Robert Friedberg remains CEO; Jessica Rowen stays on the seller side of the handoff. HealthEdge Investment Partners and United Western Group are the sponsors. (Link)
  21. Medallion acquires Andros, an NCQA-certified credentials verification organization, creating a credentialing platform covering more than one million providers. Medallion, a San Francisco AI-assisted credentialing and payer-enrollment platform, acquired Andros, an NCQA-certified CVO serving health plans, health systems, provider groups and telehealth companies since 2013. The combination brings more than one million providers across nearly 400 organizations and health plans onto one platform. Andros verifies data on more than 8 million providers and runs about 300,000 credentialing checks a year. Health-plan customers will move onto Medallion’s automated verification tools and AI outreach agents. (Link)
  22. Abry Partners–backed Centauri Health Solutions of Tempe, Arizona acquires Iowa-based Benny the Benefits Navigator to expand its SSI/SSDI eligibility technology. Centauri acquired Benny the Benefits Navigator, an Iowa startup founded in 2024 by Jeremy Shapiro, James Vancel and Joel Segre. Its AI platform replaces paper forms with a conversational digital intake for SSI and SSDI applications. Benny folds into Centauri’s Member Connect disability eligibility service, which already reaches more than 60 million lives. Latest add-on under Abry after the 2025 MedAllies purchase. (Link)
  23. Ignitus Recovery acquires AIM Health Boulder, a Colorado mental health and substance-use treatment program for young adults. Englewood-based Ignitus acquired AIM Health Boulder, a 20-year Boulder program treating adults 18–30 through PHP and IOP at the historic Earl House. Ignitus plans to keep existing programs and add residential treatment, alumni engagement and long-term recovery support. Founder Danny Conroy said he chose Ignitus to carry the program forward. CEO Steve Millette committed to no disruption for clients, staff or referral partners. (Link)
  24. Stony Brook Medicine Community Medical Group acquires South Shore Digestive Medicine, a Bay Shore, New York gastroenterology practice led by Dr. Darius Sorbi. The community physician arm of Stony Brook Medicine acquired South Shore Digestive Medicine in Bay Shore. Dr. Darius Sorbi trained in internal medicine at Stony Brook and completed his GI fellowship at Mayo Clinic. He specializes in advanced endoscopy, biliary and pancreatic disease and GI cancers. The practice is now listed at 10 Brentwood Road, Bay Shore, alongside Stony Brook GI sites in Commack and Lake Grove. Extends the SUNY-owned academic system’s coverage onto Long Island’s South Shore. (Link)
  25. AKTIV Against Cancer Merges with CancerFit Exercise-oncology combination. AKTIV is the U.S. sister of Norway’s Aktiv mot kreft — hospital gyms branded Pusterom in Norway and AKTIVcenter in the U.S., research funding at Memorial Sloan Kettering, first U.S. site at Summit Health in New Jersey. CancerFit is the digital and program counterpart. No price and no cap table on the open wire. Merger of two mission-aligned exercise-as-treatment platforms, not a clinic roll-up. (Link)
  26. Daia Orthodontics & TMJ Orthopedics acquires four former docbraces clinics in New Brunswick and Prince Edward Island, its first expansion outside the U.S. Rochester Hills, Michigan-based Daia acquired four clinics that previously operated under the docbraces name, in Grand Falls and Woodstock, New Brunswick, and Charlottetown and Summerside, Prince Edward Island. The founder-owned practice goes from one location to five. Founder Dr. Hadi Daia is certified in both the U.S. and Canada and has treated patients at these clinics since 2021, converting an existing clinical relationship into ownership. Current clinical and administrative teams stay. No outside sponsor was named. (Link)
  27. Medartis Holding (SIX: MED) Acquires M.A.R.C. Institute in Doral, Florida First permanent training site outside Europe and the group’s largest, with 36 surgical stations and capacity for 140 participants. Name and general manager Heloise Peixoto stay; the IBRA partnership continues; universities, societies and other device companies keep access. Satellite activity in São Paulo, Rio and Curitiba. Osteosynthesis implant maker buying education infrastructure, not a clinic roll-up. (Link)
  28. Xenetic Biosciences (NASD: XBIO) to Acquire Santersus AG in an All-Stock Exchange; Combined Company to Be Santersus Bio Agreement dated September 14, public print September 16. Swiss NucleoCapture blood-purification device plus Xenetic’s DNase platform against neutrophil extracellular traps. Santersus holders about 85%, Xenetic about 15% on a fully diluted basis. Pipeline includes Breakthrough Device-designated work in sepsis and SLE. Combined company expected to trade as Santersus Bio. Close targeted in the fourth quarter on a stockholder vote and Nasdaq listing of new shares. (Link)

Venture Deals and Other

  1. Vitruvian Partners leads Angle Health’s $600 million financing at a $2.7 billion valuation, with Town Hall Ventures, Blumberg Capital, Portage Ventures, Prudential Financial (NYSE: PRU)’s PruVen Capital and Y Combinator participating. London-based Vitruvian Partners led a $600 million equity financing in Angle Health at a headline $2.7 billion valuation. It combines a $200 million Series C with a $400 million tender offer for existing shareholders. New investor Town Hall Ventures joined existing backers Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The San Francisco company provides AI-driven health benefits to more than 5,000 small and mid-sized employers, with nearly $1 billion in annualized premiums. It reports 120% growth and four profitable quarters in a row. (Link)
  2. Thoreau leads a $100 million funding commitment to Penelope Health, with Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp participating. Thoreau, the healthcare investment platform led by former New Mountain Capital president Matt Holt, has committed $100 million to London-based Penelope Health. Existing backers Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp joined. The funding comes with a partnership to build shared infrastructure for real-time payments and clinical coverage rules. Penelope’s platform tracks insurer coverage policies for more than 200 million Americans across over 15,000 procedure and drug codes. The amount is a commitment rather than a closed round. (Link)
  3. JMI Equity leads Archy’s $50 million Series C, with TCV, Entrée Capital, Bessemer Venture Partners, CRV and Alven participating. JMI Equity led a $50 million Series C in Archy, a San Jose AI platform for running dental practices. Existing investors TCV, Entrée Capital, Bessemer, CRV and Alven joined. Total funding now stands at $97 million. Built-in AI agents handle claims and collections, visit notes, insurance eligibility, patient communications and analytics. Archy serves more than 1,000 practices in 45 states and processes over $300 million in payments a year. (Link)
  4. Catalio Capital Management leads AVAVA’s $45 million financing, made up of $30 million in equity and a $15 million debt facility. Catalio, AVAVA’s first institutional investor, led a $45 million package of $30 million in equity and a $15 million debt facility. The relationship includes $10 million of growth capital from Catalio’s Structured Opportunities Fund in 2024. Boston-based AVAVA sells aesthetic laser devices built on Focal Point Technology, which delivers energy to targeted depths in the skin. The money funds commercial expansion, new products and international growth. (Link)
  5. Obvious Ventures leads Mithrl’s $20 million Series A, with Headline and AGI House participating. Obvious Ventures led a $20 million Series A in Mithrl, a California company building AI infrastructure for drug developers. Headline, AGI House and several pharma executives participated. Its second-generation platform, Mithrl-1, pairs a proprietary biomedical model with agents that choose models and manage cost. It runs inside each client’s environment. The company says top-10 pharma companies and clinical-stage biotechs already use it, with a goal of 50% faster IND timelines. (Link)
  6. Neon leads Ayble Health’s $16 million Series A, with Unum Group (NYSE: UNM)’s Unum Ventures, Upfront Ventures, M13, Ohio-based Cleveland Clinic Ventures, DigiTx and Accomplice participating. Neon led an oversubscribed $16 million Series A in Boston-based Ayble Health. Total capital raised now exceeds $27 million. Ayble runs an AI-enabled virtual clinic for digestive conditions, sold to national health plans, large employers and benefit platforms. It reports a 47% average improvement in symptoms and at least a 3:1 return for customers. The money strengthens AI care tools and expands the company into autoimmune conditions. (Link)
  7. GOA Therapeutics Emerges from Stealth with $15.5 Million; Unveils GOA26 for Acute Alcohol Intoxication Dallas preclinical shop. In an IND-enabling porcine model after 1.2 g/kg oral ethanol, blood alcohol concentration was 61.3% lower versus control at 20 minutes. No FDA-approved drug rapidly lowers BAC today. IND targeted by year-end 2026; first-in-human work in 2027. Data were presented the same day at AAST in Dallas. (Link)
  8. Khosla Ventures leads Nara Health’s $14 million pre-seed and seed financing, with Long Journey Ventures and Superior Studios participating. Khosla led $14 million across pre-seed and seed in Nara Health, formerly Avant Health. Long Journey Ventures, Superior Studios and angels joined. The Chicago company administers health plans for self-insured employers using AI — benefits, claims, care coordination and member support. Nara has more than 25,000 members and has processed over $600 million in claims. CEO Sid Sinha said the money funds Chicago hiring and platform scale. (Link)
  9. Flare Capital Partners leads Kairon Health’s $5 million round, with Tau Ventures, Lightbank, General Advance and Pave Health Ventures participating. Flare led a $5 million round in Kairon Health, joined by Tau Ventures and existing backers Lightbank, General Advance and Pave Health Ventures. Founder Nick Bartz spent nine years at Aledade. The New York AI platform turns claims, records, admission alerts, lab and pharmacy data into task lists for staff at ACOs, health systems and physician groups. It covers more than one million patients across 30-plus states under Medicare, Medicaid and commercial value-based contracts. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 8th, 2026

LECO_Weekly-Healthcare-News_9-8-2026Download

Healthcare Weekly News and Deals

  1. Oura Inc. has publicly filed its Form S-1 with the SEC for a Nasdaq listing under the ticker OURA, with existing investors reportedly seeking up to $3 billion at a valuation above $16 billion. The public file on 3 September replaces a 21 May confidential submission and attaches audited figures. Revenue reached $1.21 billion for the nine months to 30 June 2026, up 74% from $697.6 million; fiscal 2025 revenue was $907.9 million, up 123%. Gross margin improved to 55% from 51%. The $924.3 million net loss attributable to common stockholders is a $985.0 million deemed dividend on redeemable convertible preferred — a pre-IPO capital-structure entry, not operating deterioration. Last private mark was about $11 billion in October 2025. Hardware is still roughly 80% of revenue. (Link)
  2. Yellow Wood Partners to Buy Nestlé’s Mainstream Vitamins and Supplements Platform for $1 Billion Nestlé is keeping the premium practitioner-channel brands — Solgar and Pure Encapsulations — and selling the mass-market Holistic Health VMS book. That is how large strategics are now splitting consumer health: retain clinician-recommended margin, exit volume. Yellow Wood has run this carve-out playbook before. GLP-1-driven changes in nutrition behavior are reshuffling category economics; add-on activity is expected. (Link)
  3. Medtronic plc has committed about $700 million to Cornerstone Robotics and taken distribution rights to Cornerstone’s Sentire surgical system in selected markets outside the United States. Sentire will sit beside Hugo (Medtronic’s robotic-assisted surgery (RAS) system) rather than replace it. The system was built in-house, finished multi-specialty trials and received CE Mark in May 2026 for general, gynecologic, thoracic and urologic minimally invasive surgery, on top of China and Singapore approvals. Cornerstone runs three global R&D hubs, six business centers and a 30,000-square-meter plant in China; the console is dual-capable. Hugo is already in more than 35 countries, with procedures expected to exceed 50,000 this fiscal year. Rights apply only where Sentire is already market-approved. (Link)
  4. American Healthcare REIT Spends $696 Million on Eight Class A Senior Housing Communities, Launching a New LCB Operating Relationship The eight communities total 867 units across Massachusetts, Connecticut, New Jersey, Pennsylvania, Delaware and Georgia. They were carved from a ten-community sale; AHR walked the other two to a second buyer at its allocated basis — a structure owners should note when a single buyer will not take the whole book. The same week AHR closed six Kensington Senior Living communities for about $572 million, part of an eight-community, 745-unit portfolio priced near $873 million and described as well below replacement cost. Year-to-date investments now exceed $2 billion. (Link)
  5. LTC Properties Pays $200 Million for Four Minnesota SHOP Communities at a 7% Year-One Cap Rate The four assets are 453 independent living, assisted living and memory-care units with an average age of nine years. Unlevered IRR is guided to the low- to mid-teens. About $167 million of the check came from selling 13 Texas skilled-nursing centers — a rotation out of triple-net SNF into operator-aligned seniors housing, now 38% of annualized NOI. Operator is Lifespark. Published cap-rate and IRR targets are uncommon and give private owners a reference bid. (Link)
  6. Medtronic plc (NYSE: MDT) has agreed to invest up to $80 million in Israel’s Pi-Cardia Ltd., securing global distribution rights to the ShortCut device and an option to acquire the company for up to $210 million plus earn-outs. The check is staged into Rehovot; exclusive ShortCut distribution starts in 2027; the option is milestone-based. ShortCut is the first FDA-cleared leaflet-modification tool for valve-in-valve TAVR patients at risk of coronary obstruction, with successful leaflet splitting in every pivotal-trial patient. Structural Heart GM Jorie Soskin framed it as preparing for complex-anatomy TAVR demand rather than buying the company today. (Link)
  7. Cresco Labs Inc. (CSE: CL; OTCQX: CRLBF) has closed the purchase of PharmaCann Penn, LLC for $50 million in cash and a seller note, adding nine operating medical-marijuana dispensaries in Pennsylvania The deal is cash-free and debt-free against a normalized working-capital target and is described as immediately accretive to revenue, margin and cash flow. Pennsylvania is the second-largest U.S. medical cannabis market, with more than $1.1 billion of sales last year. The stores deepen an existing Mid-Atlantic retail bench rather than opening a new state. No earn-out was disclosed. (Link)
  8. Fortrea Holdings Inc. (NASD: FTRE) will buy Worldwide Clinical Trials’ Early Phase Services unit for about $45 million in cash. The package is a 200-bed GCP clinical pharmacology unit in San Antonio, a 60,000-square-foot GLP bioanalytical lab in Austin and a biospecimen store in Pflugerville. Fortrea picks up captive large- and small-molecule bioanalysis and more first-in-human beds. Worldwide keeps late-stage oncology, neuroscience, internal medicine and rare disease and will still place Phase I work through a services alliance. Close is subject to licenses and those agreements. Barclays and Mintz advised Fortrea; BroadOak and Greenberg Traurig advised Worldwide. (Link)
  9. Discovery’s Vitality Acquires Icario in a Reported R958 Million Deal, Building a Payer Platform Covering 30% of U.S. Health Plans The combined stack reaches 19 million members, including eight of the ten largest U.S. plans. The parties themselves did not disclose value; the R958 million figure is from South African press. Member engagement is now a Stars-and-risk-adjustment revenue lever rather than a wellness line item. The buyer is a non-U.S. strategic writing a check for scaled U.S. payer distribution — a class domestic sellers should not overlook. (Link)
  10. HCA Healthcare, Inc. (NYSE: HCA) has sold Dominion Hospital in Falls Church, Virginia to New York-based senior care operator Hill Valley Healthcare for $25 million. The buyer, founded in 2018, runs more than 40 facilities across six states. This is its first behavioural-health asset and part of a push into Virginia. Dominion treats children, adolescents and adults, including eating-disorder and trauma programmes. HCA keeps 430 inpatient behavioural beds and 19 outpatient programmes in the state. (Link)
  11. PACS Group, Inc. (NYSE: PACS) has signed definitive agreements to acquire the operations of 32 Florida skilled nursing facilities leased from Omega Healthcare Investors, Inc. (NYSE: OHI).  Florida is the company’s 21st state. The package adds 4,049 licensed beds concentrated in the Tampa, St. Petersburg and Orlando corridor, with close expected in the fourth quarter. Chairman and CEO Jason Murray framed the state as demographically driven growth; shares rose 3.3% premarket. (Link)
  12. H.I.G. Capital has completed the acquisition of Outcomes One, the Orlando-based clinical network services and pharmacy technology provider led by Chief Executive Jude Dieterman. The Miami firm, with $75 billion under management, bought through an affiliate; terms were undisclosed. The asset pairs network reach with recurring software: a clinical network touching roughly 85% of U.S. pharmacies, more than 10 million interventions in 2025 across 130 million covered lives, and platforms including Rx30, Computer-Rx and Outcomes Premium. Managing Director Arjun Mohan framed the thesis as elevating the pharmacy’s role in care delivery. Customers span national chains, health systems, specialty and long-term care, and independents. (Link)
  13. CVC, through its Strategic Opportunities III platform, has agreed to invest in Unitex Textile Services LLC alongside the Potack family, taking the first outside equity in the healthcare linen group’s 100-year history.  Founded in 1922 and based in Elmsford, New York, Unitex is the leading outsourced healthcare textile manager in the Northeast, serving more than 5,000 hospitals, outpatient sites and nursing homes through an automated processing network. Chairman Michael, CEO Robert and President David Potack keep a significant stake and continue to run the company. Proceeds fund operations, commercial work, digital capability, greenfield sites and bolt-ons. The underwriting is scale, route density and long-tenured accounts. (Link)
  14. Labcorp (NYSE: LH) has acquired MLM Medical Labs, expanding its central-laboratory and biomarker network across the United States, Germany and South Africa.  Labcorp says that makes it the only independent central lab with a wholly owned network on four continents. MLM operates Africa’s first fully CAP-accredited central laboratory and adds biomarker and specialty testing for multinational trials. Labcorp employs about 71,000 people, supported more than 85% of FDA new-drug approvals in 2025 and ran more than 750 million tests. No price was disclosed. (Link)
  15. Bain Capital-backed LeanTaaS has acquired Aidin, the care transition platform founded and led by Russell Graney, to extend iQueue for Inpatient Flow through discharge and placement.  LeanTaaS is already in about 200 health systems and more than 1,200 facilities. Aidin serves 200-plus hospitals across roughly 20 systems and coordinates more than two million referrals a year through 21,000-plus post-acute providers. Published results: 0.86 days off average length of stay, placement time halved, and about $1.7 million of annual savings per hospital. Bain partner Paul Moskowitz framed the return as capturing both the avoided day and the freed bed. Terms undisclosed. (Link)
  16. Stryker (NYSE: SYK) has signed a definitive agreement to acquire privately held ZuriMED, developer of the commercialized FiberLocker System for rotator-cuff augmentation.  ZuriMED is a Zurich company out of ETH Zurich, the University of Zurich and Balgrist. FiberLocker is an FDA-cleared (510(k), late 2024) single-use system: a non-degradable polyester SpeedPatch PET felt plus a dedicated instrument that mechanically felts the patch into repaired cuff tissue. Published retear rates after cuff repair run from 24% to 94%; the device is indicated to reinforce suture or anchor repair where the soft tissue is weak. The parties will operate separately until close. (Link)
  17. Quva has acquired Central Admixture Pharmacy Services’ 503B product portfolio after CAPS, a B. Braun unit, exited 503B sterile compounding.  Named SKUs include cardioplegia, total parenteral nutrition and heparin. Quva runs more than 200,000 square feet of FDA-registered 503B plants in New Jersey and Texas and 100,000 square feet of forward distribution in Texas and Arizona, and already serves more than 3,500 U.S. hospitals. Selected products start later in 2026, with the rest over the following six months. Local CAPS 503B staff are being offered roles. (Link)
  18. VION Biosciences, based in Shaker Heights, Ohio, has closed its acquisition of Prolytix. The add-on brings regulated large-molecule bioanalytical and CMC work — PK, ADA and immunogenicity, biomarkers, method validation, release and stability — plus research reagents, plasma and coagulation proteins, IVD inputs and custom collection devices. Those lines sit next to CTL immune monitoring and Ansh Labs on a Brooke PE / LongWater / Twin Bridge platform. CEO Mark Thornton framed the gap as documentation-heavy services and workflow-critical reagents. (Link)
  19. Serent Capital-backed Aria Care Partners has acquired Precision Mobile Care, the Utah mobile dental provider led by Principal John Flanders.  The Overland Park platform already delivers dental, vision, audiology and podiatry plus insurance into skilled nursing facilities and has converted a ten-year insurance relationship into ownership. Precision serves thousands of residents in more than half of Utah’s SNFs with on-site preventive and restorative dental care. This is Aria’s third acquisition of 2026, after the February Sanford dental and vision platform in Georgia and Alabama. Aria partners with more than 3,500 facilities nationally; client-facing teams and schedules stay. (Link)
  20. Incline Equity Partners-backed West Physics Consulting, LLC has acquired Radiographic Testing Services, Inc., the Albany, New York medical physics provider.  West Physics, Atlanta-based and sponsor-backed since June, is on its ninth disclosed add-on. RTS, founded in 2011, covers nuclear medicine, diagnostic radiology, radiation oncology and Certified Radiation Equipment Safety Officer work across central New York. An Albany field office lets the platform meet New York requirements centrally and reach Boston and Philadelphia. CEO Dr. Geoffrey West cited local relationships and state regulatory familiarity. (Link)

Venture Deals and Other

  1. Noteus Partners has led a $90 million equity round in Scan.com with participation from Aviva (LSE: AV.), Concord Health Partners, YZR Capital and Oxford Capital, alongside $130 million of debt facilities from VerisFi Capital and Atempo Growth. vCombined capital is $220 million after revenue doubled to a $165 million annualised run-rate. The debt is earmarked for M&A and working capital in a U.S. imaging market where 85% of scans are still booked by fax or phone. Noteus GP Nathalie Bruls cited patient experience, provider connectivity and proprietary data; Concord’s James Olsen tied it to access and cost. More than 900,000 patients have used the network globally. (Link)
  2. Morgan Health has led a Series E of more than $125 million in Thyme Care at a valuation above $2 billion, joined by Humana Inc. (NYSE: HUM), CVS Health Ventures — the corporate arm of CVS Health Corporation (NYSE: CVS) — AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The syndicate pairs two national payers with community-oncology, health-system and employer-benefit capital. Reach is 10.5 million people across all 50 states and more than $7 billion of oncology spend, with validated 5–10% reductions in total cost of care. The company reports profitability and positive free cash flow. Proceeds also capitalise Thyme Companies, a new parent building independent oncology businesses aimed at biosimilar adoption and trial accrual. Morgan Health CEO Dan Mendelson cited continued conviction in payer-side value delivery. (Link)
  3. Ultrahuman has raised $70 million — $65 million of equity and $5 million of debt — at a reported $365 million valuation, with Qualcomm Ventures, Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital. The Bengaluru company says it has sold about 800,000 rings and is running at a $140 million revenue run-rate, targeting $200 million by January 2027. It currently uses Nordic Semiconductor silicon and is adding Qualcomm chips so more algorithms run on the ring rather than the phone or cloud. Part of the money funds a deeper link between ring physiology and Labcorp blood-testing data, plus expansion in India and the UAE. (Link)
  4. BVF Partners, L.P. has led an oversubscribed $60 million Series B in Superluminal Medicines with new investors Deep Track Capital and Perceptive Advisors joining existing backers RA Capital Management, Insight Partners, NVIDIA Corporation (NASD: NVDA), Catalio Capital Management, Eli Lilly and Company (NYSE: LLY), Cooley and Gaingels. The round funds the move from discovery platform to clinic. NVIDIA is the compute check; Lilly is both investor and GPCR collaboration partner. Proceeds take a selective, biased MC4R agonist into Phase 1 by year-end 2026 for rare genetic and hypothalamic obesity. BVF’s Harsha Paladugu cited differentiated small molecules against historically intractable GPCRs; RA Capital’s Nandita Shangari pointed to syndicate calibre as validation of platform translation. (Link)
  5. Elucid has closed an oversubscribed $55 million Series D with a new unnamed publicly traded medtech strategic investor joining IAG Capital Partners and Elevage Medical Technologies, the platform created by Patient Square Capital. The company raised after FDA clearance and reimbursement, not before. Total capital is about $185 million since 2009; valuation undisclosed. The new backer is Elucid’s fourth publicly traded strategic — an unusual concentration for software-only cardiovascular diagnostics. Plaque-IQ was cleared in October 2024 and has been reimbursable under CPT 75577 at a national average of about $1,012 per scan since January 2026. BioIntegrated FFR-CT remains in 510(k). Proceeds fund commercial expansion and clinical studies. (Link)
  6. Hi Rasmus has taken a $50 million minority growth-equity investment from Updata Partners. The Nashville ABA software company was founder-controlled and previously bootstrapped. It now serves about 1,000 organizations and 19.6 million client session hours a year and ranked No. 7 on the 2026 Inc. Regionals Southeast list on 1,069% two-year growth. Braden Snyder of Updata joins the board. No change of control; management says it does not plan another raise. (Link)
  7. EIT Pharma has closed an oversubscribed $35 million Series A led by Propel Bio Partners. EIT is taking lonafarnib, an investigational first-in-class oral therapy for chronic hepatitis D in patients already infected with hepatitis B, through FDA review. The company says it is the only oral candidate in late-stage CHD development and that the NDA has been accepted. Lonafarnib is designed for oral dosing and room-temperature storage. Good Ventures and Arrowtown joined. Proceeds fund continued FDA review, manufacturing and commercial readiness if approved, plus the rest of the infectious-disease pipeline. Safety and efficacy are not established. (Link)
  8. Labcorp Venture Fund, the strategic arm of Labcorp Holdings Inc. (NYSE: LH), has led a $32 million Series B in N-Power Medicine with continued participation from the Merck Global Health Innovation Fund of Merck & Co., Inc. (NYSE: MRK), Innovatus Capital Partners and a leading US biotech investor. The Labcorp check is the second industry-leader investment in the Redwood City company after Merck GHI. The product is ProECA, which builds prospective, trial-grade external control arms from routine community cancer care and is meant to cut randomisation, sample size and timelines. The initial NSCLC programme runs across more than 40 community oncology sites and is already used by sponsors for early-phase and Phase 4 work. Colorectal and prostate platforms follow later this year. Proceeds scale the network and pharma partnerships. (Link)
  9. Chicago-based PatientIQ has closed a $30 million Series C led by Hughes & Company, with Health Enterprise Partners and August Capital. The outcomes platform now covers 870-plus healthcare organizations, 17 million patients and more than 70 million collected outcomes across 20-plus specialties and 50-plus EHR integrations, including Epic, Oracle Cerner and Athenahealth. It powers registries for AAOS, AANS and STS. Proceeds fund deeper specialty and health-system penetration, real-world evidence for device and life-science customers, and a direct-to-patient marketplace. Travis Hughes joins the board. (Link)
  10. Madrona and General Catalyst have led the close of NewDays’ seed round at $16 million, as the Seattle AI dementia care company launches in Nevada. The same pair co-led the original $7 million seed; this take-up brings the seed to $16 million total. The pitch is a staffing bottleneck: cognitive therapies work but depend on a small bench of trained clinicians. NewDays pairs monthly or twice-monthly telehealth visits with unlimited sessions with an AI companion, Sunny. Research presented at the Alzheimer’s Association International Conference in July showed patients outperforming historical decline curves by about 18 months of preserved function — on 24 patients. Nevada is the sixth state. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 31st, 2026

LECO_Weekly-Healthcare-News_8-31-2026Download

Healthcare Weekly News and Deals

  1. Sword Health to acquire OrangeDot, the parent company of Headspace, in an all-cash transaction reported between $200-$300 million. Sword Health, last valued at about $4 billion after raising just under $500 million, is buying OrangeDot for cash, with OrangeDot surviving as a wholly owned subsidiary. The $200–300 million range is a severe markdown against the roughly $3 billion at which Headspace and Ginger combined in 2021 and sits below the $321 million Headspace had raised. The deal follows Sword’s $285 million purchase of Kaia Health and extends its move from musculoskeletal care into behavioural health alongside its Mind and Dawn products. The Massachusetts filing dates from 22 July; the effective date is 14 September. (Link)
  2. American Healthcare REIT, Inc. (NYSE: AHR) has completed a $197 million acquisition of two Northern California senior housing communities from a joint venture between Affinius Capital and Alliance Residential Co. American Healthcare REIT has bought Sonrisa Senior Living in Roseville, rebranded Avella at Roseville, and The Watermark at Almaden, 545 units in total, for $197 million. Sonrisa alone traded at $94.1 million. The buyer has now completed roughly $1.4 billion of senior living acquisitions in 2026 and is pursuing a pipeline including $953 million under executed agreements, among them an $873 million Kensington portfolio. Senior housing occupancy reached 89.9% in the second quarter. Note the source headline wrongly casts the REIT as seller. (Link)
  3. Thomas Park Investments has acquired a four-property, $70 million medical outpatient portfolio from Stewart Investment Properties. The Annapolis healthcare real estate platform paid $70 million for 165,637 square feet across three Mid-Atlantic submarkets. The package is 1420 Beverly Road in McLean, a 47,185-square-foot building fully leased and anchored by MedStar Health; 6849 Old Dominion Drive in McLean, 69,330 square feet and 89% leased with Johns Hopkins Medicine as anchor; Children’s National at the former Takoma Theatre on Fourth Street NW in Washington, 24,140 square feet; and Luminis Health Easton Pavilion in Easton, Maryland, 24,982 square feet and fully leased to Luminis Health. Each asset is health-system anchored with remaining term and contractual rent growth. (Link)
  4. Ambulatory Partner Holdings has agreed to pay $54 million for a 60% stake in Atlas Surgery Center, the physician-owned neurosurgical ASC in Amherst, New York. Ambulatory Partner Holdings, an LLC owned equally by Rafael Axen, M.D., Matthew Jenkins and Ann Sariego, is buying 60% from seven of the nine physician members who together hold 90%.. Atlas, at 50 George Karl Boulevard, is a multispecialty Article 28 centre known for outpatient neurosurgery, angiograms, carotid stenting and complex spine, running on the order of 3,000 cases a year. Purchase price is equity-funded. New York’s Public Health and Health Planning Council has the establishment application on its 17 September agenda. (Link)
  5. The Federal Trade Commission has approved the final consent order clearing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The FTC finalised its order on 25 August, letting Ascension close a $3.9 billion purchase first agreed in mid-2025. Six centres go to SC Affiliates, a national ASC operator, and a seventh in Panama City to Florida Gastroenterology Center, a physician group already holding a minority stake. The divestitures cover Nashville, Panama City, Tulsa, Waco and Wichita, where the agency alleged reduced competition in gastroenterology, ophthalmology and orthopaedic outpatient procedures. Ascension must also give the FTC prior notice of ASC acquisitions in those metros for ten years. AmSurg operates more than 250 centres across 34 states. (Link)
  6. McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC from Blackstone (NYSE: BX) for approximately $2.25 billion. McKesson is paying roughly $2.25 billion for the Bethesda-based business after a multi-year Blackstone hold. The buyer is underwriting a services asset rather than a distribution one: biomarker intelligence, laboratory services, a global CRO, market access consulting and commercialisation support. That fits a portfolio McKesson has been reshaping by shedding non-core assets and concentrating capital in oncology and specialty, where Oncology & Multispecialty revenue rose 33% to $14.2 billion in fiscal first quarter 2026. The target will report inside that segment. Closing is subject to customary conditions and regulatory clearances. (Link)
  7. Eli Lilly and Company (NYSE: LLY) to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform aimed at pathogenic autoantibodies. Consideration is cash up to $2.875 billion, covering an undisclosed upfront payment and contingent milestones. Cambridge-based Merida is building biologics that selectively degrade disease-causing antibodies while sparing normal immune function. Lead program MER511 is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing reductions in pathogenic thyroid-stimulating antibodies and a favourable safety profile. A preclinical program, MER769, targets food allergy, asthma and chronic spontaneous urticaria. Merida launched last year with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures. Close is expected in the fourth quarter, subject to customary clearances. (Link)
  8. Argenx SE (Euronext & Nasdaq: ARGX) completed a $2.2 billion all-cash acquisition of Forte Biosciences, Inc. (Nasdaq: FBRX) at $77.00 per share. The close, announced 27 August, follows a cash tender that drew about 87% of Forte shares. The deal adds FB102, which has clinical proof-of-concept in vitiligo and celiac disease and potential application across multiple autoimmune indications, to argenx’s immunology portfolio. The original agreement was signed 27 July at a 40.5% premium to Forte’s then-close. The transaction extends a 2026 pattern of large-cap immunology buyers paying for de-risked, mechanism-differentiated assets rather than waiting for later-stage readouts. Forte is now a wholly owned subsidiary and will delist from Nasdaq. (Link)
  9. Advent International has signed a definitive agreement to acquire a majority stake in New Zealand Clinical Research Group in a transaction local press valued at roughly NZ$1 billion, with Waterman Capital and clinician shareholders rolling over. Advent, one of the largest global private equity firms, is buying majority control of NZCR Group, a physician-led clinical trials platform operating across New Zealand and Australia under the NZCR, CMAX, Optimal and Fusion brands. Advent’s own release did not print a price; BusinessDesk and the Australian Financial Review put the equity value at about NZ$1 billion. Waterman Capital, which held 52%, and clinician shareholders are keeping a significant minority. Close is targeted for the fourth quarter subject to regulatory approvals. Advent will partner with CEO Tony Moffatt to deepen sponsor relationships and extend the network internationally. (Link)
  10. Radiology Partners has signed a definitive agreement to acquire Everlight Radiology from UK private equity firm Livingbridge in a cross-border teleradiology transaction reported at roughly $1 billion (approximately A$1 billion, or about US$715 million). Livingbridge is exiting Everlight after taking majority control in 2021 for a reported US$344 million, having itself bought the asset from Intermediate Capital Group. Everlight’s 800-plus consultant radiologists across 40-plus countries read on a follow-the-sun basis, roughly 2.5 million exams a year for 340-plus clients, avoiding premium US night-shift rates. Radiology Partners intends to extend Mosaic Drafting AI across the acquired network. The 17 August edition covered Livingbridge putting the asset up for sale with Radiology Partners named as bidder; this is the signed agreement. Regulatory clearances pending. (Link)
  11. TowerBrook Capital Partners to acquire a majority stake in Korean-American women’s wellness brand Rael for 400 billion won ($290 million), buying out a shareholder register including SoftBank Ventures, Unilever Ventures, Lotte Shopping, Shinsegae and GS Retail. TowerBrook is paying 400 billion won, about $290 million, for majority control of Rael, according to people familiar with the matter. The sponsor is buying a consumer health asset with a proven digital channel: Rael became Amazon’s top-selling sanitary pad label on an organic feminine care proposition. The cap table it is taking out is unusually broad for a brand of this size, spanning venture investors SoftBank Ventures and Unilever Ventures alongside strategic Korean retail capital from Lotte Shopping, Shinsegae and GS Retail. The deal is a rare cross-border consumer exit for Korean sponsors in a market skewed toward beauty. (Link)
  12. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has filed Chapter 11 and entered a stalking-horse sale with Teva Pharmaceuticals at $57.5 million upfront with milestones up to $125 million. BioXcel and two OnkosXcel subsidiaries petitioned in Delaware on 27 August to run a court-supervised 363 sale of substantially all assets. Teva Pharmaceuticals International GmbH is the stalking-horse bidder for $57.5 million in cash, assumption of specified liabilities, and up to $67.5 million of contingent development payments — a ceiling of $125 million if milestones hit. The estate includes IGALMI, the approved dexmedetomidine sublingual film for agitation, and the pending BXCL501 at-home filing. Teva posted a $5.7 million good-faith deposit and framed the bid as consistent with its Pivot to Growth business-development screen. Higher bids can still emerge at auction. (Link)
  13. Beyond Air, Inc. (Nasdaq: XAIR) has agreed to sell its controlling stake in NeuroNOS Israel Ltd. to Tel Aviv-listed UNIVO Pharmaceutical Industries (TASE: UNVO) for equity, warrants and up to $32.5 million in milestones. Beyond Air is selling 5,000,000 ordinary shares, about 58% of NeuroNOS on a fully diluted basis. Consideration is UNIVO ordinary shares equal to 19.99% of UNIVO’s issued capital, five-year warrants on a further 19.99% of UNIVO awards exercisable at $0.01, plus up to $6.5 million in cash development milestones and up to $26 million in commercial milestones. NeuroNOS is developing blood-brain-barrier-crossing small molecules that regulate nitric oxide, including BA-102 for autism spectrum disorder and Alzheimer’s and BA-101 for glioblastoma, both still preclinical. The sale lets Beyond Air concentrate on its nitric-oxide device franchise. (Link)
  14. Savista, the Alpharetta-based healthcare operations and revenue cycle management company, has acquired ABW Medical, an ambulatory revenue cycle management provider serving federally qualified health centres, medical groups, MSOs and virtual care platforms. Savista is buying its way out of a single-segment concentration. Its existing base is acute: more than 800 clients across 49 states, an Epic-certified training workforce and cancer registry services built over 35 years. ABW Medical adds the non-acute end, including community health centres, FQHCs, rural providers and virtual care, plus preferred RCM partner status inside the athenahealth ecosystem. That diversifies EMR exposure away from Epic dependence and adds safety-net billing around Medicaid wraparound payments. Clients pick up Savista’s global delivery scale and eligibility, coding and A/R tooling. (Link)
  15. Eqwal Group has acquired Atlantic Pro Care, the Portland, Maine prosthetics and orthotics practice, extending the French patient-care network’s East Coast footprint. Eqwal is a global prosthetics and orthotics patient-care group that already owns Steeper in the UK and has been rolling up US clinics including United Prosthetics, American Orthopedics, Optech, South Beach Prosthetics and Prosthetic & Orthotic Group. Atlantic Pro Care, founded in 1993 by J.P. Donovan in Portland, fits custom devices for patients with upper- and lower-limb loss and spinal conditions and handles assessment, fabrication, fitting and rehab. The buyer framed the tuck-in as deepening US patient-care density rather than adding a product brand. No purchase price was published. (Link)
  16. Thurston Group, the Chicago healthcare-focused private equity firm, has made a platform investment in Pixel Health, a Holyoke, Massachusetts provider of IT consulting and managed services to hospitals and large physician groups. Thurston is entering healthcare IT services for the first time through Pixel Health, founded in 2001 and built into a multi-brand group spanning strategy and transformation consulting, managed IT services, and product sales and licensing. Managing partner Dan Davis framed the deal as consistent with the firm’s practice of backing leaders in high-growth healthcare verticals. The sponsor has installed Brad Mondschein, previously the company’s chief operating and legal officer, as chief executive. The investment case is outsourced IT for health systems that cannot staff internally against rising cybersecurity, interoperability and AI-integration complexity. (Link)
  17. BV Investment Partners-backed Imagenet has acquired Analytica Consulting, the California data engineering and artificial intelligence firm, in a transaction that closed on 21 August 2026. Imagenet is moving from transaction-processing BPO toward an end-to-end data and AI solutions position for payers. Analytica Consulting, founded in 2015, brings cloud data warehousing, automated ETL pipelines, enterprise visualisation, data science and governance. The commercial angle is in-situ modernisation: layering pipelines and machine learning models on top of health plans’ existing core systems rather than requiring replacement, and applying prescriptive models to denial trends across digital mailroom, claims adjudication and contact centre lines. The target retains its government, life sciences, manufacturing and education clients. (Link)
  18. Switchboard Health has acquired virtual musculoskeletal provider Livara Health, formerly SpineZone, and closed an oversubscribed equity round of more than $5 million backed by First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. The acquisition converts Switchboard from a referral navigation software layer into a value-based care delivery provider. Livara, founded by orthopaedic spine surgeon Kamshad Raiszadeh, pairs orthopaedic physicians with physical therapists and psychosocial providers, and its outcomes were independently validated by the Validation Institute in 2024 at a 43% reduction in MSK spend, largely through avoided low-value surgery. Switchboard reports routed patient volume up 500% over nine months. This is its second acquisition in under a year after Conduce Health. The raise draws both companies’ existing investors plus new backers. (Link)
  19. WellStack, the Madison, Wisconsin healthcare data platform led by Chief Executive Rich Waller, has acquired DeLorean Artificial Intelligence, the predictive analytics and risk stratification company led by Chief Executive Severence MacLaughlin, to build an end-to-end healthcare decision intelligence platform.WellStack runs an agentic healthcare data platform with a managed data foundation, analytical studio and modular Decision Hubs. DeLorean AI adds continuous evaluation of clinical, claims and operational data to flag emerging risks, predict adverse events and recommend next actions. The combination targets the gap between data aggregation and intervention, moving customers from what happened to what to do about it. Client case studies cite improved patient adherence, reduced avoidable utilisation and revenue optimisation. MacLaughlin framed the merger as necessary for deep integration with health system data lakes and EMRs. (Link)
  20. ALIS, the Chicago-based senior living clinical and operational software platform, has acquired the Ella and elbi technology platforms from TapRoot Interventions & Solutions in its first acquisition. ALIS has grown organically from a clinical EHR into an operating system unifying CRM, clinical, billing, AI and business intelligence; Ella and elbi are its first bought capability. The platforms deliver point-of-care, AI-native guidance to frontline caregivers handling dementia and behavioural episodes, using non-pharmacological, person-centred interventions. The economics sit in two measurable outcomes senior living operators are judged on: fewer high-risk behavioural incidents and reduced psychotropic medication reliance, both increasingly tied to reimbursement and length of stay. The platforms also capture behavioural data for population health reporting. Announced at the buyer’s user conference. (Link)
  21. Globus Medical, Inc. (NYSE: GMED) has acquired Higgs Boson Health, the Durham, North Carolina digital healthcare experience company incubated out of Duke University, to build out its surgical intelligence pillar. What Globus is buying is a team of software developers and AI scientists rather than a revenue base. The acquirer frames the technology as part of a surgical intelligence pillar linking outcomes and analytics in a closed loop across the full episode of care. The stated long-term target is 95% good outcomes at ten years in musculoskeletal surgery, and management is treating patient and provider experience as the missing layer of that ecosystem. The deal follows a second quarter reported on 6 August in which sales grew and non-GAAP EPS guidance was raised. (Link)
  22. Ekoscan Integrity Group, the Eurazeo-backed French non-destructive testing group, has signed a definitive agreement to acquire the US-based NDT Digital business of Carestream Health, Inc., adding the INDUSTREX computed and digital radiography portfolio. Ekoscan is buying Carestream Health’s US NDT Digital unit — computed radiography systems, digital radiography detectors and imaging software under the INDUSTREX brand — plus the commercial, applications and service organisation in Rochester, New York. Radiographic imaging joins the buyer’s existing ultrasound and eddy-current lines, making a multi-method inspection platform for aerospace and defence, oil and gas and power generation. Carestream is narrowing to healthcare imaging. Ekoscan has been an active consolidator, backed by Eurazeo and EDF Pulse Ventures. Closing is expected in the fourth quarter of 2026. (Link)
  23. Golden State Dermatology, the physician-owned platform backed by Sorenson Capital and Yukon Partners, has acquired Summit Dermatology in Colorado Springs, its first move outside California. Golden State Dermatology has been a California story, roughly 45 locations and more than 125 providers built through steady practice tuck-ins with Sorenson Capital and Yukon Partners behind it. Summit Dermatology, led by board-certified dermatologists Kevin Whaley and Jeanne Osborn, is the first out-of-state platform entry and opens the Colorado market. The target offers medical and procedural dermatology including skin cancer screening and Mohs micrographic surgery, and retains its location, phone number and staff. Founder Ed Becker frames the strategy as building the leading comprehensive dermatology network across the Western US. (Link)
  24. Regent Surgical has added Integrated Surgical Center of Arizona, an Avondale multispecialty centre owned by IMS Care, AZ Heart Arrhythmia Associates and Valley GI Consultants, to its ambulatory surgery centre network. Regent Surgical, founded in 2001 and headquartered in Nashville, is a developer and operator of ambulatory surgery centres that has grown from 8 to 32 centres in eight years on site-neutral payment economics. The Arizona addition is a physician-partnership structure rather than an outright buyout: ISCA is owned by IMS Care, the state’s largest independent multispecialty physician group, cardiac electrophysiology group AZ Heart Arrhythmia Associates, and Valley GI Consultants. The strategic value is cardiac migration into outpatient settings across greater Phoenix. Regent also runs a joint venture with Cleveland Clinic. (Link)
  25. Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, the Walnut Creek, California practice founded in 1979 and led by Dr. Gillian Hamilton and Dr. Erica Weiss. Great Point Partners, the Greenwich healthcare-only investor, backed VetnCare in 2022; Geary is the seventh acquisition since, and the second in roughly six weeks after Holistic Veterinary Care in Oakland on 14 July. The company has more than doubled in size in three years under that ownership. The model is regional density rather than national scale: VetnCare concentrates in Northern California, and Geary deepens the East Bay position with a practice offering wellness and preventive care, diagnostics and imaging, surgery, dental and senior pet care. (Link)
  26. Gravity 360, Inc., the Covington, Kentucky parent of Gravity Diagnostics, has acquired Med-Lake Laboratory, LLC, a CLIA-certified, CAP-accredited high-complexity clinical laboratory in Milledgeville, Georgia. Gravity 360 is building a regional laboratory platform across the southern United States, and Med-Lake gives it an operating base outside Kentucky for the first time. Founded in 2018, the target serves physician practices, skilled nursing facilities, behavioural health providers, judicial programmes and urgent care clinics across Georgia and Alabama, with a testing portfolio spanning clinical toxicology, blood and clinical chemistry, PCR infectious disease and reference services. Rather than consolidating volume into Kentucky, the buyer is retaining the Georgia laboratory, its team and its courier network as the foundation for further expansion. (Link)
  27. The Landes Group, the Dallas healthcare real estate investment firm, has completed its acquisition of Encore Medical Center in Bryant, Arkansas from Arkansas Heart Hospital and finalised a long-term lease with the University of Arkansas for Medical Sciences, financed with CGA Capital. The Landes Group has closed on a 108,055 square foot, 53-bed hospital and simultaneously locked in its tenant. UAMS gains capacity without deploying capital, paying annual rent reported at roughly $8.16 million with 2.1% escalation and a purchase option in ten years. That structure is the firm’s core strategy: single-tenant, net-leased healthcare assets where ownership is paired with financing that preserves provider capital. Longstanding financing partner CGA Capital supported the transaction, extending a relationship spanning more than $1.2 billion. Arkansas Heart Hospital operates the facility through 30 September, with UAMS assuming control on 1 October. (Link)
  28. Calera Capital-backed Cypress Health Partners has added Boston Sports Medicine’s ten outpatient clinics to the Bay State Physical Therapy network, effective 27 August. Cypress Health Partners, the Calera Capital-backed outpatient physical therapy platform operating across the Northeast, has partnered with Boston Sports Medicine, one of Greater Boston’s most established physical therapy providers. BSM’s ten outpatient clinics join the Bay State Physical Therapy network, expanding access across Massachusetts communities after more than 25 years of referral-base building. The transaction lands as the outpatient PT sector shifts from pure density plays toward a second phase of value creation focused on patient acquisition and reimbursement yield from existing clinical capacity. (Link)

Venture Deals and Other

  1. RA Capital has joined a $120 million Series C for AusperBio Therapeutics that will fund the Phase 3 registrational program for a functional hepatitis B candidate, taking capital raised since 2024 past $340 million.AusperBio, which operates from Hangzhou and California, closed the $120 million Series C on 31 August led by a new strategic investor, with RA Capital Management joining and existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments returning. Proceeds fund the Phase 3 registrational program and commercialisation work for lead candidate AHB-137, advance next-generation candidate AHB-171, and support combination-therapy development for chronic hepatitis B. The round is the largest venture check in this week’s book and is a China-plus-US therapeutics financing rather than a services deal. (Link)
  2. The Gates Foundation has committed up to $35 million to ProFound Therapeutics, including $20 million initially, to find placental and serum protein targets for preeclampsia and eclampsia. ProFound Therapeutics uses its ProFoundry platform against the expanded human proteome. The Gates money funds discovery of novel proteins expressed in placenta and serum from women with preeclampsia and eclampsia, new drug targets and biomarkers, and a disease-specific AI tool. The initial $20 million is committed now; the balance is contingent on program progress. This is foundation capital rather than a priced venture round, and it sits beside rather than inside the company’s existing equity syndicate. Announced 27 August. (Link)
  3. TJ Parker, general partner at Matrix, has led a $26 million Series A in Metriport, with participation from ARTIS Ventures and Y Combinator, taking the open-source healthcare data infrastructure company to $28.4 million raised. Matrix led the round through TJ Parker, whose stated rationale is channel evidence: he sees dozens of consumer health companies each year and the strongest ones increasingly build on Metriport. The company was founded in 2022 by former AWS engineer Dima Goncharov and Colin Elsinga. The differentiator investors are underwriting is open-source infrastructure against legacy black-box interoperability tools, accessible via a single API, cloud warehouse connection or native EHR application. Customers include Amazon One Medical, Sollis Health and Color Health. Proceeds fund AI chart summarisation and agentic workflows for care teams. (Link)
  4. Define Ventures has led a $25 million Series B in Arintra, with participation from existing investors Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. Define Ventures led the round, taking Arintra’s total funding to $51 million. The investment case rests on measurable throughput: the platform processes more than $5 billion in annual claim value for health systems representing over $50 billion in combined net patient revenue, and reports a 5.1% increase in compliant revenue capture, 32% cost reduction and 43% fewer coding-related denials. Endeavor Health, an early adopter, backed both the Series A and B. Partner Chirag Shah argued no prior solution had been comprehensive enough to move the bottom line. Proceeds fund enterprise expansion and deeper specialty coverage. (Link)
  5. Wing Venture Capital, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures and SV Angel have backed Outer Bio with roughly $23 million as the Cambridge company exits stealth with its Yuna human-skin platform. What the syndicate is funding is a data asset rather than a clinical one: Yuna keeps full-thickness human skin alive and measurable for four weeks against roughly one week for conventional explants, generating longitudinal multi-omic data that improves the machine learning models over time. The commercial route is consumer skincare first, with partnership revenue already flowing. Founded in 2020 by chief executive Michael Polansky, with Stefani Germanotta on the board. The round size and the syndicate signal investors are underwriting a compounding biological dataset rather than a single product launch. (Link)
  6. Saga Ventures has led $22.5 million in seed and Series A funding for Hike Medical, joined by Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc. and angels including Monaco chief executive Sam Blond and Jerod Mayo. Max Altman of Saga Ventures led the financing, and his stated thesis is vertical integration: owning the entire value chain end to end rather than layering software on a broken industry. The market economics justify it, with roughly $100 billion spent annually on orthotics, prosthetics and durable medical equipment and, per the company’s own research, 60 cents of every dollar lost to waste, remakes and fraud. Operating metrics already show remake rates cut from one in 15 to one in 400. Strategic investor and commercial partner Orthofeet participated. Proceeds fund hiring in San Francisco and manufacturing in Peoria, Illinois. (Link)
  7. Costanoa has led a $17 million Series A in Onos Health, joined by Flare Capital Partners and strategic investor CVS Health Ventures, the corporate venture arm of CVS Health Corporation (NYSE: CVS). The strategic money matters commercially: Aetna is already a customer, and the company says it is trusted by three of the six largest US health plans. Costanoa partner Amy Cheetham framed behavioural health as one of the largest and least understood categories in healthcare, with wide cost variation and low correlation to quality. Reported outcomes include a 35% improvement in clinical standard adherence and a 6%-plus cut in behavioural health programme costs within twelve months. Proceeds scale the decision-support tools payers use to manage behavioural benefit design and utilisation. (Link)
  8. Neotribe Ventures, Listen and Village Global have funded a $12 million round for Boston-based Legato, which has emerged from stealth to commercialise AI hearing-assistance glasses. Neotribe founder and managing director Kittu Kolluri framed the investment as a bet against the industry’s design orthodoxy, arguing that decades spent making hearing aids invisible has suppressed adoption and that positioning assistance as a style choice is the route to the market. The defensible asset is intellectual property: four granted patents and more than 20 pending applications. The competitive set is formidable, including EssilorLuxottica’s Nuance Audio and hearing features from Apple and Samsung. Proceeds fund a launch in the coming months and further development. (Link)
  9. August Global Partners has led a $10 million convertible note financing for Shape Memory Medical, joined by fellow new investor Taiwania Capital alongside existing backers HBM Healthcare Investments, Earlybird Venture Capital and WexMed II. The convertible structure defers valuation until clinical readouts land. Partner Davian Sim argued clinicians treating aortic aneurysms and dissections have long relied on repurposed materials, and identified an inflection point as two programmes advance. Proceeds fund follow-up in the AAA-SHAPE pivotal trial, fully enrolled at 180 patients across 48 centres, and the FLAGSHIP feasibility study. Both new investors also support Asia-Pacific expansion. HEAL Venture Lab assisted; the note sits ahead of those readouts rather than pricing the company now. (Link)
  10. Redesign Health has provided $2.25 million in seed funding to OmicsBank, the clinical data infrastructure company founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel.Redesign Health is the sole named backer of this seed round. Head of ventures Neil Patel was explicit about the underwriting order, saying the firm backed the founders first and the market second, citing five companies built between them and the relationship-intensive work of winning hospitals one at a time. The asset being capitalised is a deployed data network: infrastructure inside 90-plus hospitals and laboratories across South Asia, Southeast Asia and the Middle East, covering 12.5 million longitudinal records, 30 million DICOM images, six million pathology slides and 500,000 whole-genome sequences. Proceeds fund US and biopharma expansion. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 24th, 2026

LECO_Weekly-Healthcare-News_8-24-2026Download

Healthcare Weekly News and Deals

  1. Francisco Partners to take Weave Communications (NYSE: WEAV) private for $650 million in an all-cash deal at $7.40 per share. The price is a 34% premium to Weave’s Monday closing price, and the company will delist after going public in 2021. The sponsor is buying a vertical platform serving independent medical, dental, optometry and veterinary practices, a customer base most software companies overlook. Weave generated $239 million of fiscal 2025 revenue, up 17%, and $65.5 million in the first quarter of fiscal 2026, also up 17%, yet its market value sits well below the $1.4 billion peak. Francisco Partners raised more than $75 billion and previously bought AdvancedMD for $1.125 billion. (Link)
  2. Universal Health Services (NYSE: UHS) has closed its $835 million debt-financed acquisition of virtual behavioral care provider Talkspace (NASD: TALK). The transaction valued Talkspace at $5.25 per share and was financed with debt. Talkspace keeps its brand and organizational structure, with CEO Jon Cohen reporting directly to UHS President and CEO Marc Miller. The target reported $229 million in revenue, $4.8 million in net income and $15.8 million in adjusted EBITDA in 2025, and runs a virtual network of more than 6,000 behavioral health professionals. Behavioral health already generated about 43% of the buyer’s $17.4 billion 2025 revenue, and UHS expects the deal to be slightly accretive to adjusted net income in the first year after closing. (Link)
  3. Thoma Bravo has to take Accelerant (NYSE: ARX) private at $20.25 per share in an all-cash deal valuing the specialty insurance risk exchange above $4 billion, with existing backer Altamont Capital Partners rolling over. The offer is a 49% premium to Accelerant’s closing price on 12 August 2026. Altamont Capital Partners, which controls around 82% of voting rights, supports the deal, and Altamont and the founders intend to keep an equity interest alongside Thoma Bravo. Thoma Bravo has committed equity, so completion does not depend on additional financing, and shareholders receive a 6% annual ticking fee if insurance regulatory approvals delay closing. Senior partner A.J. Rohde tied the thesis to MGA market growth. (Link)
  4. BioMarin (NASD: BMRN) to acquire Alesta Therapeutics for $275 million BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage oral small molecule for hypophosphatasia. BioMarin will pay $275 million upfront and up to $215 million in development and regulatory milestones. Alesta will spin out all non-ALE1 assets prior to closing. ALE1 is being evaluated in a Phase 1/2a trial and has the potential to become the first oral therapy for the rare genetic bone disease. Closing is expected this quarter. (Link)
  5. Cityblock Health has signed an all-stock agreement to acquire Homeward Health and separately raised a $116 million Series E led by General Catalyst. Financial details of the all-stock acquisition were not disclosed. The $116 million Series E was led by General Catalyst and takes total capital raised past $900 million, against a $400 million 2021 round that set a roughly $5.7 billion valuation. The company says it is not focused on an exit at this time. Cityblock serves almost 200,000 members at $2.2 billion of annualized revenue, up 77% year over year, and the two businesses together will serve nearly 250,000 people. (Link)
  6. R1 to acquire Humata Health, the AI prior authorization company, to extend its Phare Operating System into payer-provider authorization workflows. Pricing was not disclosed and both parties are private. The investment case is denial prevention: prior authorization is a top-three driver of denials, and a KFF survey found one-third of insured adults call it the biggest burden in accessing care. Humata’s agentic workflows match payer policy, build AI-driven clinical bundles and manage requests to final approval, delivering up to a 96% first-pass approval rate while cutting write-offs by 30%, rescheduled appointments by 83% and staff touches by 45%. R1 folds the capability into Phare Intelligence and Payer Atlas and uses it to sell adjacent modules. (Link)
  7. Goldman Sachs Asset Management-backed Advanced Recovery Systems has acquired Promises Behavioral Health from Assured Healthcare Partners. Terms were not disclosed. Promises was previously backed by Assured Healthcare Partners, which converted its debt into equity in late 2021, after BlueMountain Capital Management bought the assets of bankrupt Elements Behavioral Health in 2018. Combined, the company operates 24 facilities in 14 states across medical detox, inpatient, residential and outpatient services. Goldman halted an auction of Advanced Recovery Systems in January, and addiction treatment dealmaking has fallen sharply, with six closings in the first half of 2026 against 19 a year earlier.(Link)
  8. General Catalyst-backed Radial has acquired TMS Health Partners, the MSO behind Mindful Health Solutions, delivering an exit for previous backer Aisling Capital. Terms were not disclosed. Radial is less than a year into its holding period with General Catalyst and has multiplied its clinical footprint with a single transaction. The combination brings Radial to 27 clinics across seven states, most of them from Mindful Health Solutions. The deal also caps a quick turnaround for Aisling Capital. Radial supports clinics with drug and device procurement, billing and RadialOS, an AI clinical decision support tools. (Link)
  9. Flexpoint sells ArtesRx to Linden Capital Partners Flexpoint Ford has completed the sale of ArtesRx, its specialty behavioral health pharmacy platform, to Linden Capital Partners. Formed in 2023, ArtesRx focuses on complex medication regimens for patients with serious mental illness, substance use disorders, and intellectual and developmental disabilities. Under Flexpoint ownership the platform expanded from three pharmacies in a single state to 16 locations across 15 states through organic growth and targeted M&A. Financial terms were not disclosed. (Link)
  10. BPOC partners with Master Medical Equipment and ReNew Biomedical BPOC has made strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies that provide capital equipment distribution, rental, repair and preventative maintenance services to the pre-hospital and post-acute markets. The Jackson, Tennessee-based businesses offer new and refurbished equipment along with biomedical service across a national footprint. Founder and CEO Mark Taylor will continue to lead the companies. Financial terms were not disclosed. (Link)
  11. Truehelm and QHP Capital-backed InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite. Terms were not disclosed. InformedDNA is a portfolio company of Truehelm and QHP Capital, and the sale follows the May 2026 divestiture of its Payment Integrity business unit. The sponsors are concentrating remaining capital behind DNAimpact, InformedDNA’s precision health platform, rather than running three businesses at once. The divested unit pairs genetics-trained specialists with evidence-based review for health plans, a capability that grows more valuable as genetic test volume and complexity compound. Truehelm partner and board member Conor Green described the process as sharpening InformedDNA’s focus. (Link)
  12. U.S. Oral Surgery Management, backed by Oak Hill Capital, has partnered with Cottonwood Oral & Maxillofacial Surgery of Albuquerque in its third New Mexico transaction. Terms were not disclosed and both parties are private. USOSM is a management services organization that works exclusively with oral and maxillofacial surgeons and now spans 31 states. The specialist-only mandate is the differentiator against general dental consolidators, and single-practice tuck-ins remain the primary growth mechanism. CEO Doug Drew pointed to clinical reputation, patient care and safety as the selection criteria for the practice. USOSM provides operational, financial and administrative support to surgeons alongside wealth creation. (Link)
  13. Integrated Dermatology has entered the Kentucky market through a partnership with Knuckles Dermatology, which now operates as Integrated Dermatology of Kentucky. Terms were not disclosed and both parties are private. The partnership took effect August 18, 2026 and covers patients in Corbin, Richmond and surrounding southeastern Kentucky communities. Dr. Knuckles continues to practice, and two board-certified family nurse practitioners, Lauren Hayes and Jordan Patterson, join to expand provider capacity. Established in 2004, Integrated Dermatology operates in nearly 30 states and offers dermatologists profit-sharing and full clinical autonomy while handling operational and administrative work centrally.(Link)
  14. Concentra (NYSE: CON) has completed the acquisition of four Minnesota Occupational Health medical centers in the Twin Cities, taking its statewide network to 10 sites. Terms were not disclosed. The four acquired centers sit in Coon Rapids, Eagan, St. Paul Midway and Shakopee, and began operating as Concentra on August 17. Concentra has served Minnesota since 2018 and will now run 10 medical centers across the state. The buyer also plans significant investment in the St. Paul Midway center to make it a regional flagship. The economics rest on density and employer cross-selling across injury care, physical therapy, drug testing and DOT exams. (Link)
  15. Momentum Health Partners has expanded its investment in Desert Pain Specialists, the Rancho Mirage, California interventional pain management practice it first backed in 2023. The amount was not disclosed. The Phoenix-based platform deployed additional capital into Desert Pain Specialists following the acquisition and integration of Dr. Roland Reinhart’s pain management practice. The new capital funds physician recruitment, service line expansion and operational growth across California’s Coachella Valley, where the practice has posted growth in new patient volumes since integrating. Partner Ryan Harper framed the follow-on as confidence in the team. Momentum invests across autism therapy, developmental therapies, behavioral health and specialty ambulatory care. (Link)
  16. SEVA has made a growth equity investment in healthcare price transparency company Serif Health, the first outside institutional capital the San Francisco business since 2020 launch. Terms were not disclosed. The round is Serif Health’s first outside institutional capital since it launched in 2020, and SEVA founder and managing partner Shalin Mehta joins the board. Serif cleans, validates and standardises pricing data from hundreds of payers and thousands of hospitals through its Signal platform, used by more than 250 organisations to benchmark rates, evaluate networks and track market dynamics. Proceeds accelerate sales and expand a pipeline of product features and data APIs, following the 2026 launch of Signal Ask, a plain-language query tool. (Link)
  17. Providence Equity Partners to acquire a majority stake in CheckedUp, with Varsity Healthcare Partners joining as strategic minority. Terms were not disclosed. Providence is acquiring alongside the co-founders, who continue to lead the company, and Varsity Healthcare Partners as a healthcare services-focused minority investor. CheckedUp reaches >17,000 specialty healthcare providers and 15 million patients through waiting-room televisions and interactive exam-room wallboards, and works with most of the top 40 pharmaceutical manufacturers. Providence is underwriting this as a digital out-of-home media asset, consistent with prior positions in OUTFRONT Media, DoubleVerify and Smartly.io. (Link)
  18. Cypress Ridge Capital-backed Cresso Health has partnered with Slate Financial, the Southwest Medicare and health insurance distributor. Terms were not disclosed. Cresso Health is backed by New York-based healthcare investor Cypress Ridge Capital. The logic is distribution roll-up economics. Slate gains access to Cresso’s carrier relationships, distribution infrastructure, proprietary marketing and lead-generation tools and compliance toolkit, while Cresso extends its field presence. CEO Frank Pistone described the goal as an omni-channel, multi-product platform serving the senior market. Cypress Ridge invests exclusively in healthcare with a thematic, growth-oriented approach. (Link)
  19. Rockmont Partners has exited RepScrubs, the automated scrubs dispensing platform, with THL named as acquirer in Healthcare DealHub’s headline. Terms were not disclosed. Healthcare DealHub titles the transaction as THL acquiring RepScrubs from Rockmont Partners, while the deal note itself describes the buyer as undisclosed. Rockmont led a secondary purchase in the business in 2024, making this a short hold. RepScrubs runs an automated scrubs dispensing platform that manages vendor credentialing and enforces policy compliance for perioperative vendors at hospitals and surgery centers. The asset sits in digital and health technology, which has recorded 289 tracked deals year to date. (Link)
  20. Berks Community Health Center to merge with Lancaster-based Union Community Care, a distress-driven nonprofit combination pending regulatory approval. No purchase price applies. Board vice chair Missy Orlando named two financial triggers, starting with a sharp drop in federal Medicaid funding from January that could cost roughly 100,000 Berks County residents their benefits. The center has also struggled to collect patient payments and lost several providers over the past year. Union Community Care operates 25 locations across Lancaster, Lebanon and Chester counties, covering family medicine, urgent care, dental, school-based care, behavioral health and pharmacy. (Link)
  21. Mitsui Chemicals (Tokyo: 4183) has completed its acquisition of Utah-based dental products maker Ultradent Products, making it a wholly owned subsidiary alongside existing dental unit Kulzer. The deal closed on August 14, ahead of the September 2026 schedule, after competition and investment approvals came through early. Mitsui is making oral care the third earnings pillar of its Life & Healthcare Solutions segment and targeting the number two position in global dental materials. The company expects more than $40 million in annual synergy by fiscal 2030. Integration moves the oral care global headquarters to the United States, with Ultradent CEO Dirk Jeffs also taking over as Kulzer CEO while Kulzer’s Chris Holden becomes Chief Strategy and Integration Officer of MC Dental Holdings America.(Link)
  22. Osage Venture Partners-backed Curavit Clinical Research has acquired the CRO assets of Lindus Health, which is shifting to its own therapeutic pipeline as Lindus Therapeutics. Terms were not disclosed. The transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets. What Curavit bought is European delivery capability, not scale for its own sake: the combined business can now run decentralized, hybrid and traditional trials across North America and Europe under one operational partner. Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, tied the thesis to sponsors needing more flexible, technology-enabled approaches to generating clinical evidence. CEO Joel Morse positioned the platform against both regional niche CROs and legacy providers. (Link)

Venture Deals and Other

  1. 8VC and Town Hall Ventures have led a $53 million Series D in Hopscotch Primary Care. 8VC and Town Hall Ventures led the round, with existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures participating and new investors including the Autism Impact Fund, Kleiner Perkins chairman John Doerr, Heritage Provider Network founder Dr. Richard Merkin and the Leon Levine Foundation. Founded in 2021, Hopscotch serves more than 15,000 patients across the rural Southeast, concentrated in western North Carolina. Investors have hard numbers to point at: a Net Promoter Score of 89, patient retention above 90%, medical loss ratio improvement of more than 25 percentage points over two years and profitable operations in western North Carolina. (Link)
  2. Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital have funded Network Bio’s $50 million launch alongside an NVIDIA partnership. Network Bio, a Palo Alto company building AI models trained on human biological data, launched on August 19 with $50 million from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. The money funds a research network with Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz, supplying tissue and blood samples paired with longitudinal clinical outcomes across immunology, metabolic, cardiovascular and autoimmune disease. Investors are paying for exclusive data access rather than a clinical asset. The launch came with an NVIDIA partnership to scale the models. (Link)
  3. InnovaHealth Partners led Channel Medsystems’ Series C to $30 million, backing the commercial expansion of the Cerene endometrial cryotherapy platform. The Berkeley medical technology company has reached $30 million in an ongoing Series C led by InnovaHealth Partners. InnovaHealth has backed Channel Medsystems since 2021. Proceeds fund commercial organization expansion, physician and patient awareness, professional education and training, clinical evidence generation and market development infrastructure. The raise follows a commercial relaunch of the platform. Founder and Managing Partner Mortimer Berkowitz III pointed to unmet need in women’s health backed by clinical evidence and an experienced leadership team. (Link)
  4. MaxQ Medical raises $31.5 million Series A backed by Olympus MaxQ Medical has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with participation from Hillside Capital. The financing advances the company’s transurethral imaging-and-therapy platform for prostate disease, the first spinout from Orchard Ultrasound Innovation. The system combines real-time imaging with tissue-selective therapy in a single outpatient procedure, initially targeting BPH with planned expansion into focal therapy for prostate cancer. Proceeds support clinical program advancement and team expansion. (Link)
  5. Leal Therapeutics announces $30 million Series A extension Leal Therapeutics has completed a $30 million second close of its Series A, adding Eli Lilly as a new investor alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund and others. Proceeds will advance LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, through initial readout of its newly initiated Phase 1b/2a trial in schizophrenia, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 ALS study. (Link)
  6. Werewolf Therapeutics and Ambros Therapeutics announce merger and concurrent $150 million private placement Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics have entered an all-stock merger agreement accompanied by an oversubscribed $150 million private placement co-led by RA Capital and Janus Henderson. The combined company, to operate as Ambros Therapeutics and trade as AMBX, will advance neridronate in the pivotal CRPS-RISE Phase 3 trial for Complex Regional Pain Syndrome Type 1. Capital is expected to fund operations through Phase 3 topline results, planned NDA submission and into the first half of 2029. (Link)
  7. Gossamer Bio announces up to $250 million structured private placement Gossamer Bio has arranged a structured private placement of up to $250 million, including $150 million of committed capital, to fund development of seralutinib through potential FDA approval. The financing extends runway for late-stage clinical and regulatory activities surrounding the company’s lead pulmonary arterial hypertension program. (Link)
  8. Biotechnology investor Bob Nelsen has led a $20 million round in Astromech, joined by Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, lifting the Colossal Biosciences spinout to a $3.8 billion valuation. The round was led by Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing total capital raised to $60 million. The valuation is unusual relative to check size, and what investors are buying is founder pedigree and a data position rather than near-term revenue. Astromech was co-founded by Ben Lamm and geneticist George Church, spun out of Colossal Biosciences, and uses 3.8 billion years of evolutionary history as a primary training signal. Longevity is the proving ground, with 46 longevity-associated genes mapped so far. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 10th, 2026

LECO_Weekly-Healthcare-News_8-10-2026Download

Healthcare Weekly News and Deals

  1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
  2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
  3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
  4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
  5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
  6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
  7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
  8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
  9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
  10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
  11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
  12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
  13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
  14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
  15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
  16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
  17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
  18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
  19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
  20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
  21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
  22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
  23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
  24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
  25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
  26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
  27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
  28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
  29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
  30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
  31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

  1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
  2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
  3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
  4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
  5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Lawrence Evans & Co is pleased to announce the successful closing of a $30M Refinance / Growth Capital facility for a Healthcare Revenue Cycle Management (RCM) Platform

Lawrence, Evans & Co., LLC is pleased to announce the successful closing of a refinance and growth acquisition financing for a rapidly expanding healthcare revenue cycle management (RCM) platform.

LECO successfully led the transaction while simultaneously navigating multiple acquisitions across several countries—and the associated overseas legal and regulatory requirements—to support the owner’s non-dilutive refinancing and acquisition line of credit needs.

The transaction was led by Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC.

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 20th, 2026

LECO_Weekly-Healthcare-News_4-20-2026Download

Healthcare Weekly News and Deals –April 20th, 2026

  1. White House Issues Executive Order to Accelerate Medical Treatments for Serious Mental Illness, with Focus on Psychedelic Research and Patient Access. The White House announced an executive order directing federal agencies to accelerate the research, development, and regulatory review of innovative treatments for serious mental illness, with particular emphasis on psychedelic compounds such as ibogaine for treatment-resistant cases. The order instructs the FDA to issue National Priority Vouchers for Breakthrough Therapy-designated psychedelic drugs, facilitates patient access under the Right to Try Act (including Schedule I substances), and allocates at least $50 million through ARPA-H for state partnerships and clinical trial support. It also calls for enhanced collaboration and data sharing with the VA, plus expedited rescheduling reviews for qualifying substances post-Phase 3. The action aims to address the mental health crisis impacting over 14 million U.S. adults and elevated suicide rates among veterans by promoting treatments offering enduring therapeutic benefits beyond traditional medications. (Link)
  2. McKesson (NYSE: MCK) Signs Agreement with Apollo Funds for $1.25 Billion Strategic Minority Interest in Medical-Surgical Solutions Business. McKesson Corporation (MCK) has entered into an agreement with Apollo Funds for a $1.25 billion investment in convertible preferred equity, representing an approximately 13% minority stake in its Medical-Surgical Solutions (MMS) business at a ~$13 billion enterprise valuation. McKesson will retain majority ownership, operating control, and financial consolidation of the unit. The transaction represents a key milestone in McKesson’s planned separation and future IPO of MMS, which supplies essential products and solutions to non-acute care settings. Apollo’s expertise in carve-outs is expected to support MMS as a well-capitalized standalone company. The deal remains subject to regulatory approvals. (Link)
  3. Global Medical Response (NYSE: GMRS) Files S-1 Registration Statement in Advance of Planned IPO. Global Medical Response (GMR Solutions Inc.) has filed an S-1 registration statement with the SEC for an initial public offering of Class A common stock on the NYSE under the symbol GMRS. The company, the largest U.S. provider of emergency medical services (EMS) and integrated alternate-site care, operates air and ground ambulances across approximately 1,400 counties and serves about 5.5 million patients annually with roughly 34,000 employees. For 2025, GMR reported net revenue of approximately $5.74 billion and Adjusted EBITDA of $1.19 billion. (Link)
  4. Eli Lilly (NYSE: LLY) Acquires Texas ADC Specialist CrossBridge Bio in ~$300 Million Deal to Strengthen Oncology Pipeline. Eli Lilly (LLY) has acquired Houston-based CrossBridge Bio, a preclinical antibody-drug conjugate (ADC) specialist, in a transaction valued at approximately $300 million (mix of upfront and milestones). CrossBridge’s technology, originating from the University of Texas Health Science Center, features advanced linker stability and multi-payload capabilities, with lead TROP2-targeting dual-payload candidate CBB-120 expected to enter the clinic in 2026. The deal further builds on Lilly’s recent ADC acquisitions and internal efforts, enhancing its position in next-generation cancer therapies. (Link)
  5. UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Advancing Epilepsy Pipeline with Regenerative Cell Therapy. UCB has agreed to acquire Neurona Therapeutics, gaining its lead asset NRTX-1001, a pluripotent stem cell-derived neuronal cell therapy currently in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The total transaction value reaches up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestones. The acquisition advances UCB’s leadership in epilepsy by introducing regenerative science approaches aimed at restoring neural circuitry and providing durable seizure control. NRTX-1001 has received FDA RMAT and EMA PRIME designations. The deal is expected to close by the end of Q2 2026, subject to antitrust clearance. (Link)
  6. Organon (NYSE: OGN) Shares Surge Following Reports of Acquisition Interest from Leading Private Equity Firms CVC Capital Partners and TPG. Organon (OGN) witnessed a 25% increase in its stock price amid market reports that CVC Capital Partners and TPG are exploring a potential multi-billion dollar acquisition of the company. The interest from these prominent private equity firms highlights the perceived value in Organon’s diverse portfolio of women’s health products, biosimilars, and established brands. While a formal deal has not been confirmed, the involvement of CVC and TPG suggests a significant investment opportunity in the pharmaceutical space, as financial sponsors look for stable, cash-flow-generative assets. Investors are keeping a close watch on OGN as potential bidding activities could reshape the women’s health sector. (Link)
  7. Avanos Medical, Inc. (NYSE: AVNS) Agrees to $1.272 Billion Acquisition by American Industrial Partners to Transition the Company into Private Ownership. Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) for approximately $1.272 billion in an all-cash transaction. AIP’s investment values Avanos at $25.00 per share, representing a significant premium for stockholders. The deal will transition Avanos into a private entity, allowing the company to focus on long-term growth and its innovation roadmap without public market pressures. AIP intends to leverage its deep operational expertise to enhance Avanos’s competitive position in the medical technology sector. The acquisition is expected to close in the second half of 2026, marking a new chapter for the medtech firm. (Link)
  8. Gyde Acquires Benavest, Marking Its Second Deal in Two Weeks as AI-Enabled Health Insurance Brokerage Expands. Gyde, an AI-powered health insurance brokerage platform that launched in January 2026 with $60 million in funding, has acquired Benavest, a national agency specializing in consumer health plans including individual ACA, ICHRA, and Medicare products. The deal follows Gyde’s recent acquisition of Medicare brokerage Avid Health. Benavest brings scalable distribution infrastructure and leadership expertise, which Gyde plans to support with its AI-driven GydeOS platform. No financial terms were disclosed. (Link)
  9. Signant Health, Supported by Financial Sponsors Harvest Partners, Genstar Capital, and Foresite Capital, Enters into a Definitive Agreement to Acquire Ametris. Signant Health has signed a definitive agreement to acquire Ametris, a global leader in digital health solutions, with the backing of private equity firms Harvest Partners, Genstar Capital, and Foresite Capital. This acquisition integrates Ametris’s clinical trial data management and sensor technologies into Signant’s evidence-generation platform. The move is a strategic play by the financial sponsors to consolidate the eClinical technology market, creating a more comprehensive suite of tools for pharmaceutical sponsors. By acquiring Ametris, Signant Health aims to enhance its capabilities in capturing high-quality clinical evidence across virtual, hybrid, and traditional trial models globally. (Link)
  10. BTX Precision, via Financial Sponsors L Squared Capital Partners and CFT Capital Partners, Completes the Strategic Acquisition of Maitland Engineering. BTX Precision has acquired Maitland Engineering to expand its precision manufacturing platform, supported by financial sponsors L Squared Capital Partners and CFT Capital Partners. This acquisition follows a series of strategic moves by BTX, including a recent continuation vehicle led by L Squared and backed by HarbourVest Partners. The investment in Maitland Engineering strengthens BTX Precision’s capabilities in producing complex, high-tolerance components for the medical and aerospace industries. L Squared Capital Partners continues to drive the platform’s buy-and-build strategy, focusing on integrating specialized regional manufacturers to create a dominant, national high-precision engineering entity with significant operational scale. (Link)
  11. CPIhealth, Supported by Financial Sponsor Iron Path Capital, Acquires Midwest Interventional Spine Specialists and Serenity Surgical Center. CPIhealth, a portfolio company of private equity firm Iron Path Capital, has acquired Midwest Interventional Spine Specialists (M.I.S.S.) and Serenity Surgical Center. This acquisition adds two clinical locations and an ambulatory surgery center to CPIhealth’s interventional pain management platform, expanding its presence in the Indiana and Illinois markets. Iron Path Capital’s investment facilitates the integration of five additional physicians and multiple nurse practitioners into the platform. This deal underscores the firm’s strategy of consolidating regional pain management practices to build a multi-state infrastructure capable of delivering advanced, cost-effective interventional spine care through a standardized clinical and administrative model. (Link)
  12. Brado AI Strengthens its Conversational Engagement Platform Through the Strategic Acquisition of ProviderIQ from Hatchleaf. Brado AI has acquired the ProviderIQ asset from Hatchleaf to enhance its precision routing and patient-provider matching capabilities. This acquisition allows Brado AI to integrate clinically informed data and real-world operational workflows into its Conversational Engagement Platform (CEP). By acquiring the technology co-developed with clinicians from Johns Hopkins, Brado AI is investing in more accurate demand-supply alignment for large healthcare systems. The deal reflects Brado AI’s commitment to reducing patient leakage and optimizing provider utilization. The investment highlights a growing trend of AI companies acquiring specialized clinical data tools to provide deeper insights and better ROI for health system partners. (Link)
  13. D2 Solutions Acquires PromodRx to Expand Patient Access and Engagement Technologies for Pharmaceutical and Medical Device Manufacturers. D2 Solutions has completed the acquisition of PromodRx, a cloud-based platform designed to accelerate patient access to prescription medications. This strategic investment expands D2 Solutions’ service offerings in market access, reimbursement support, and patient engagement. By integrating PromodRx’s technology, D2 Solutions strengthens its UltraTouch Verify and Engage platforms, helping pharmaceutical clients navigate complex prior authorization and benefit verification processes. The acquisition is intended to reduce therapy initiation delays and improve patient adherence, positioning D2 Solutions as a more comprehensive commercialization partner in an increasingly complex pricing and policy environment within the life sciences sector. (Link)
  14. H2 Health, a Portfolio Company of Grant Avenue Capital, Expands into Arkansas Through the Strategic Acquisition of Advanced Physical Therapy. H2 Health, backed by private equity firm Grant Avenue Capital, has acquired Advanced Physical Therapy (APT), a practice with six locations in the Little Rock, Arkansas market. This investment marks H2 Health’s expansion into a new state, bringing its total footprint to over 300 clinics across 13 states. Grant Avenue Capital continues to provide the financial resources for H2 Health’s aggressive buy-and-build strategy in the outpatient rehabilitation sector. The acquisition of APT allows H2 Health to leverage its centralized administrative infrastructure to improve operational efficiencies at the local level while expanding access to high-quality physical and occupational therapy services. (Link)
  15. Afterburner Capital and Council Capital Successfully Exit Their Investment in Advanced Care Partners Following an Eight-Year Growth Period. Private equity firms Afterburner Capital and Council Capital have announced the successful exit of their portfolio company, Advanced Care Partners (ACP). During their eight-year investment period, the sponsors helped ACP scale its pediatric and adult private duty nursing services across Georgia and Florida. The exit represents a significant milestone for Afterburner and Council Capital, who focused on professionalizing ACP’s management and clinical infrastructure to drive growth. This transaction highlights the strong investor demand for home-based care platforms that provide high-quality services to medically fragile populations, as financial sponsors seek exits that demonstrate successful clinical and operational scaling in the healthcare services market. (Link)
  16. Stellus Rx, a Portfolio Company of WindRose Health Investors, Acquires Tria Health to Create an Integrated Pharmacist-Led Chronic Care Platform. Stellus Rx, which is backed by WindRose Health Investors, has acquired Tria Health to expand its pharmacist-led pharmacy care management capabilities. This acquisition merges Stellus Rx’s dispensing solutions with Tria Health’s chronic condition support services for self-insured employers. WindRose Health Investors is supporting this combination to create a differentiated platform that reduces the total cost of care through improved medication adherence and clinical outcomes. The investment underscores WindRose’s strategy of backing companies that deliver cost-effective healthcare solutions. The unified entity aims to leverage shared data and clinical expertise to better manage complex patients across the healthcare continuum. (Link)
  17. Mobia Medical (MOBI) Files for a $100 Million Initial Public Offering Led by BofA Securities, J.P. Morgan, and Goldman Sachs to Advance its Vagus Nerve Stimulation Technology. Mobia Medical (MOBI), a developer of neurostimulation devices for chronic stroke recovery, has filed with the SEC to raise up to $100 million in an initial public offering. The IPO process is being led by joint bookrunners BofA Securities, J.P. Morgan, and Goldman Sachs, alongside BTIG and Wolfe | Nomura Alliance. The company, which generated $32 million in revenue in 2025, intends to use the proceeds to expand its commercial organization and fund further R&D for its Vivistim system. This filing signals a major step for the venture-backed company as it transitions into the public markets to capitalize on the $30 billion stroke recovery sector. (Link)

Venture Deals and Other

  1. Avo (AvoMD) Secures $10 Million Series A Funding Led by Noro-Moseley Partners with Participation from AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, Scrub Capital, Dunamu & Partners, Mirae Asset Capital, and Futureplay. Avo (formerly AvoMD) has successfully closed a $10 million Series A funding round to advance its AI-powered clinical decision support platform. The round was led by Noro-Moseley Partners, featuring a broad syndicate of investors including AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, and Scrub Capital. International support came from Korean firms Dunamu & Partners, Mirae Asset Capital, and Futureplay. The capital will be utilized to scale Avo’s generative AI copilots within major EHR systems, helping clinicians integrate real-time medical knowledge and hospital protocols directly into their digital workflows to improve patient outcomes. (Link)
  2. Bain Capital Life Sciences Backs Beeline Medicines with $300 Million in Capital to Develop Five Clinical Programs Acquired from Bristol Myers Squibb (BMY). Beeline Medicines has emerged from stealth with a massive $300 million investment commitment from Bain Capital Life Sciences. The venture-backed biotech is focused on advancing a portfolio of five clinical-stage programs originally discovered by Bristol Myers Squibb (BMY), targeting autoimmune and inflammatory diseases. This strategic investment allows Beeline to accelerate late-stage clinical development for assets like afimetoran, a TLR7/8 inhibitor. Bain Capital’s funding provides the necessary runway for Beeline to operate as an agile, clinical-stage entity, leveraging established pharmaceutical intellectual property to address significant unmet needs in the immunology and gastrointestinal sectors. (Link)
  3. Pulnovo Medical Announces Oversubscribed $100 Million Financing Round with Strategic Investment from Medtronic. Pulnovo Medical, a pioneer in innovative therapies for pulmonary hypertension, closed an oversubscribed $100 million financing round featuring a strategic investment from Medtronic. The capital will support the advancement of Pulnovo’s clinical programs and commercialization efforts for its pulmonary artery denervation technology. This marks a significant vote of confidence from one of the world’s leading medtech companies in the growing field of interventional pulmonary hypertension treatments. (Link)
  4. Joyful Health Raises $17 Million in Series A Funding Led by CRV with Support from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. Joyful Health, an AI-driven financial infrastructure provider for the healthcare industry, has secured $17 million in Series A funding. The investment was led by CRV, with participation from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. The company plans to use this capital to expand its workforce and accelerate the development of its “financial operating system,” which helps healthcare providers automate revenue cycle management and recover unpaid insurance claims. The investors highlighted Joyful Health’s ability to leverage AI to identify processing breakdowns and prioritize high-value recovery opportunities for resource-constrained medical practices. (Link)
  5. Keebler Health Announces $16 Million Series A Investment Led by Flare Capital Partners and Sands Capital to Expand AI Capabilities for Unstructured Clinical Data. Keebler Health has closed a $16 million Series A round led by Flare Capital Partners, with significant participation from Sands Capital. The funding will scale Keebler’s LLM-native platform, which is designed to unlock insights from unstructured clinical documentation—such as provider notes and imaging reports—to improve risk adjustment and value-based care accuracy. Investors noted that Keebler’s technology addresses a critical gap in the market where 80% of patient data remains underutilized. This capital injection will support team expansion and the deployment of real-time clinical insights aimed at enhancing both financial performance and patient outcomes for healthcare systems. (Link)
  6. Worki Secures $2.75 Million in Pre-Seed Funding Led by Founders Fund and Y Combinator to Scale its Healthcare Recruitment and Workforce Management Platform. Healthcare staffing startup Worki has raised $2.75 million in a pre-seed round led by Founders Fund and Y Combinator. The investment targets the growing labor crisis in healthcare by providing a mobile-first platform that simplifies recruitment and scheduling for both providers and facilities. Founders Fund and Y Combinator are backing Worki’s mission to reduce industry reliance on expensive third-party staffing agencies through a more streamlined, automated hiring process. The new capital will be used to enhance the platform’s AI-driven matching capabilities and expand its reach across North American health systems struggling with nurse and technician shortages. (Link)